<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39728945</article-id><article-id pub-id-type="pmc">PMC11680118</article-id>
<article-id pub-id-type="doi">10.3390/vetsci11120605</article-id><article-id pub-id-type="publisher-id">vetsci-11-00605</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Venom of <italic toggle="yes">Vipera ammodytes ammodytes</italic>: Proteomics, Neurotoxic Effect and Neutralization by Antivenom</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7134-4677</contrib-id><name><surname>Ivanovi&#x00107;</surname><given-names>Sa&#x00161;a R.</given-names></name><xref rid="af1-vetsci-11-00605" ref-type="aff">1</xref><xref rid="c1-vetsci-11-00605" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0159-8281</contrib-id><name><surname>Re&#x00161;etar Maslov</surname><given-names>Dina</given-names></name><xref rid="af2-vetsci-11-00605" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Rubi&#x00107;</surname><given-names>Ivana</given-names></name><xref rid="af2-vetsci-11-00605" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0723-7815</contrib-id><name><surname>Mrljak</surname><given-names>Vladimir</given-names></name><xref rid="af2-vetsci-11-00605" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4074-590X</contrib-id><name><surname>&#x0017d;ivkovi&#x00107;</surname><given-names>Irena</given-names></name><xref rid="af3-vetsci-11-00605" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Borozan</surname><given-names>Nevena</given-names></name><xref rid="af4-vetsci-11-00605" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8014-3121</contrib-id><name><surname>Gruji&#x00107;-Milanovi&#x00107;</surname><given-names>Jelica</given-names></name><xref rid="af5-vetsci-11-00605" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6404-397X</contrib-id><name><surname>Borozan</surname><given-names>Sun&#x0010d;ica</given-names></name><xref rid="af6-vetsci-11-00605" ref-type="aff">6</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Di Cerbo</surname><given-names>Alessandro</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-11-00605"><label>1</label>Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Belgrade, Bulevar Oslobo&#x00111;enja 18, 11000 Belgrade, Serbia</aff><aff id="af2-vetsci-11-00605"><label>2</label>Laboratory of Proteomics, Clinic for Internal Diseases, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia; <email>drmaslov@vef.unizg.hr</email> (D.R.M.); <email>irubic@vef.unizg.hr</email> (I.R.); <email>vmrljak@vef.hr</email> (V.M.)</aff><aff id="af3-vetsci-11-00605"><label>3</label>Institute of Virology, Vaccines and Sera &#x0201c;Torlak&#x0201d;, Vojvode Stepe 458, 11000 Belgrade, Serbia; <email>izivkovic@torlak.rs</email></aff><aff id="af4-vetsci-11-00605"><label>4</label>Faculty of Medicine, University of Belgrade, Dr Suboti&#x00107;a 1, 11000 Belgrade, Serbia; <email>nevena.borozan@yahoo.com</email></aff><aff id="af5-vetsci-11-00605"><label>5</label>Department of Cardiovascular Research, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia; <email>jeca@imi.bg.ac.rs</email></aff><aff id="af6-vetsci-11-00605"><label>6</label>Department of Chemistry, Faculty of Veterinary Medicine, University of Belgrade, Bulevar Oslobo&#x00111;enja 18, 11000 Belgrade, Serbia; <email>sborozan@vet.bg.ac.rs</email></aff><author-notes><corresp id="c1-vetsci-11-00605"><label>*</label>Correspondence: <email>si34826@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>11</volume><issue>12</issue><elocation-id>605</elocation-id><history><date date-type="received"><day>07</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>In this study, we first investigated the composition of the crude venom of the most venomous European snake, <italic toggle="yes">Vipera ammodytes</italic>, using proteomic analysis. The venom of this snake contains &#x003b2;-neurotoxins&#x02014;phospholipases A2; therefore, the neurotoxic effect was tested on neuromuscular preparations of the diaphragm of rats. We have shown that venom leads to a progressive decrease in the contractility of the diaphragm. After the administration of the antivenom, a protective effect was achieved, as the progressive decrease in diaphragm contractility was abolished. In addition, the antivenom completely neutralized the activity of phospholipases A2 under in vitro conditions. The investigation of the activity of Na<sup>+</sup>/K<sup>+</sup>-ATPase in the neuromuscular preparation of the diaphragm showed that the venom leads to a pronounced reduction in the activity of this enzyme. This reduction in enzyme activity was reversible, as the antivenom almost completely restores the activity of Na<sup>+</sup>/K<sup>+</sup>-ATPase in the neuromuscular preparation of the diaphragm.</p></abstract><abstract><title>Abstract</title><p>Deep proteomic analyses identified, in total, 159 master proteins (with 1% FDR and 2 unique peptides) from 26 protein families in the venom of <italic toggle="yes">Vipera ammodytes ammodytes (Vaa).</italic> Data are available via ProteomeXchange with the identifier PXD056495. The relative abundance of PLA2s is 11.60% of the crude venom, of which 4.35% are neurotoxic Ammodytoxins (Atxs). The neurotoxicity of the venom of <italic toggle="yes">Vaa</italic> and the neutralizing effect of the antivenom were tested on the neuromuscular preparation of the diaphragm (NPD) of rats. The activity of PLA2 in the venom of <italic toggle="yes">Vaa</italic> and its neutralization by the antivenom were determined under in vitro conditions. The <italic toggle="yes">Vaa</italic> venom leads to a progressive decrease in NPD contractions. We administered pre-incubated venom/antivenom mixtures at various ratios of 1:2, 1:10 and 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) and observed the effects of these mixtures on NPD contractions. The results show that the mean effective time (ET<sub>50</sub>) for NPD contractions with the 1:20 mixture is highly significantly different (<italic toggle="yes">p</italic> &#x0003c; 0.001) from the ET<sub>50</sub> for the venom and the ET<sub>50</sub> for the 1:2 and 1:10 mixture ratios. We also found a highly significant (<italic toggle="yes">p</italic> &#x0003c; 0.001) reduction in Na<sup>+</sup>/K<sup>+</sup>-ATPase activity in the NPD under the influence of the venom. The reduction in the activity of this enzyme was reversible by the antivenom. Under in vitro conditions, we have achieved the complete neutralization of PLA2 by the antivenom. In conclusion, the antivenom abolished the venom-induced progressive decrease in NPD contractions in a concentration-dependent manner. Antivenom with approximately the same mass proportion almost completely restores Na<sup>+</sup>/K<sup>+</sup>-ATPase activity in the NPD and completely neutralizes the PLA2 activity of the venom in vitro.</p></abstract><kwd-group><kwd>proteomics</kwd><kwd>venom</kwd><kwd><italic toggle="yes">Vipera ammodytes ammodytes</italic></kwd><kwd>neurotoxicity</kwd><kwd>diaphragm</kwd><kwd>Na<sup>+</sup>/K<sup>+</sup>-ATPase</kwd><kwd>antivenom</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Science, Technological Development and Innovation of the Republic of Serbia through a Grant University of Belgrade, Faculty of Veterinary Medicine</funding-source><award-id>451-03-66/2024-03/200143</award-id></award-group><funding-statement>The study was supported by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia through a Grant University of Belgrade, Faculty of Veterinary Medicine (Contract number 451-03-66/2024-03/200143).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-11-00605"><title>1. Introduction</title><p>After the WHO classified venomous snake bites as Neglected Tropical Diseases (NTDs), there was a global scientific call to increase interest in new approaches to developing antivenoms [<xref rid="B1-vetsci-11-00605" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-11-00605" ref-type="bibr">2</xref>,<xref rid="B3-vetsci-11-00605" ref-type="bibr">3</xref>].</p><p><italic toggle="yes">Vaa</italic> (<xref rid="vetsci-11-00605-f001" ref-type="fig">Figure 1</xref>) is the most common venomous snake in Serbia, both in terms of numbers and distribution area, and at the same time, its venom has the highest toxicity [<xref rid="B4-vetsci-11-00605" ref-type="bibr">4</xref>].</p><p>Snake venoms have a very complex and chemically heterogeneous composition, in which the most abundant proteins and peptides play an important role in the immobilization and digestion of prey. Some of the snake venom proteins interfere with important biological processes in mammals, such as blood clotting and blood pressure regulation, or have toxic effects, including myotoxic, cardiotoxic and neurotoxic effect [<xref rid="B5-vetsci-11-00605" ref-type="bibr">5</xref>,<xref rid="B6-vetsci-11-00605" ref-type="bibr">6</xref>]. The main clinical manifestations of the neurotoxic effect of snake venom result from acute neuromuscular paralysis and include bulbar palsy with ptosis of the eyelids, hypotonia of the extremities and respiratory insufficiency as the clinically most important neurotoxic effect [<xref rid="B7-vetsci-11-00605" ref-type="bibr">7</xref>,<xref rid="B8-vetsci-11-00605" ref-type="bibr">8</xref>]. However, there are still no predictive models for the development of respiratory insufficiency that would significantly contribute to timely and appropriate decision-making in clinical therapy. The involvement of respiratory insufficiency during envenomation and the response to antivenom depend on the snake species, i.e., the mechanism of neurotoxicity of its venoms [<xref rid="B9-vetsci-11-00605" ref-type="bibr">9</xref>,<xref rid="B10-vetsci-11-00605" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-11-00605" ref-type="bibr">11</xref>]. Ranawaka et al. [<xref rid="B9-vetsci-11-00605" ref-type="bibr">9</xref>] list nine potential sites of action for snake neurotoxins at the neuromuscular synapse, but there are basically two types of inhibitions of neuromuscular transmission: presynaptic (&#x003b2;-neurotoxins) and postsynaptic (&#x003b1;-neurotoxins) [<xref rid="B12-vetsci-11-00605" ref-type="bibr">12</xref>]. The dominant paralytic toxins of snake venoms are the three-finger toxins (3FTx), non-enzymatic &#x003b1;-neurotoxins found exclusively in the venom of Elapidae and phospholipases A2 (PLA2), enzymatic &#x003b2;-neurotoxins found in the venom of both Elapidae and Viperidae. The toxins 3FTx and PLA2 cause a disturbance of neurotransmission at the neuromuscular synapse by different mechanisms [<xref rid="B13-vetsci-11-00605" ref-type="bibr">13</xref>]. Due to its complexity, the neurotoxic mechanism of PLA2 is still the subject of intensive research. The initial phase of PLA2 action involves the hydrolysis of phospholipids in the neurilemma of the presynaptic motor nerve terminal [<xref rid="B14-vetsci-11-00605" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-11-00605" ref-type="bibr">15</xref>]. The resulting destabilization of the lipid bilayer of the cell membrane allows for a considerable influx of Ca<sup>2+</sup> ions from the extracellular space into the cell. This uncontrolled influx of Ca<sup>2+</sup> further stresses the damaged cell membrane and leads to mitochondrial dysfunction, resulting in reduced ATP production [<xref rid="B16-vetsci-11-00605" ref-type="bibr">16</xref>,<xref rid="B17-vetsci-11-00605" ref-type="bibr">17</xref>,<xref rid="B18-vetsci-11-00605" ref-type="bibr">18</xref>]. There is also evidence that PLA2 from the venoms of Elapidae and Viperidae leads to the inhibition of the enzyme Na<sup>+</sup>/K<sup>+</sup>-ATPase in various cells, including erythrocytes [<xref rid="B19-vetsci-11-00605" ref-type="bibr">19</xref>], cardiomyocytes [<xref rid="B20-vetsci-11-00605" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-11-00605" ref-type="bibr">21</xref>], neurons of the brain [<xref rid="B22-vetsci-11-00605" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-11-00605" ref-type="bibr">23</xref>] and smooth muscle cells [<xref rid="B24-vetsci-11-00605" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-11-00605" ref-type="bibr">25</xref>].</p><p>The only specific therapy for snake envenomation is the administration of an antivenom. Important facts about the production, type and use of antivenom in Europe are listed in the next part. There are eight antivenoms for bites from <italic toggle="yes">Vipera</italic> species. The Material Safety Data Sheet (MSDS) was available for seven of them (Poland, Bulgaria, Turkey, Serbia, United Kingdom, Croatia and France; no SDS could be obtained for the Russian antivenom). None of these antivenoms are licenced by the European Medicines Agency (EMA). Of the seven antivenoms with an MSDS, six are equine antivenoms and one is a ovine antivenom. The equine antivenoms are F(ab&#x02032;)2 products, while the ovine antivenom is a Fab product [<xref rid="B26-vetsci-11-00605" ref-type="bibr">26</xref>]. The antivenom from Serbia is an equine F(ab&#x02032;)2 product. Within the family Viperidae, six antivenoms have been produced against the venom of <italic toggle="yes">V. berus</italic> or <italic toggle="yes">V. ammodytes</italic>, one against the venoms of <italic toggle="yes">V. ammodytes</italic>, <italic toggle="yes">V. aspis</italic> and <italic toggle="yes">V. berus</italic> and one against the venoms of <italic toggle="yes">V. ammodytes</italic>, <italic toggle="yes">Macrovipera lebetina</italic> and <italic toggle="yes">Montivipera xanthina</italic>. In Europe, there is no standardized protocol for the administration of antivenom. Six manufacturers recommend intramuscular administration, while two manufacturers recommend intravenous administration of the antivenom [<xref rid="B26-vetsci-11-00605" ref-type="bibr">26</xref>,<xref rid="B27-vetsci-11-00605" ref-type="bibr">27</xref>].</p><p>Proteomic analyses have shown that the venom of <italic toggle="yes">V. berus</italic> is less complex than that of <italic toggle="yes">V. ammodytes</italic>. A particularly important finding is that the content of the PLA2 is lower in <italic toggle="yes">V. berus</italic> compared to that in <italic toggle="yes">V. ammodytes</italic>. Therefore, antivenoms developed against the venom of <italic toggle="yes">V. berus</italic> are not sufficiently effective in the treatment of severe cases of <italic toggle="yes">V. ammodytes</italic> bites [<xref rid="B27-vetsci-11-00605" ref-type="bibr">27</xref>,<xref rid="B28-vetsci-11-00605" ref-type="bibr">28</xref>]. It is obvious that the variability in the composition of the venom has a decisive influence on the design of antivenoms. In this context, proteomic analyses are of great importance as they provide fundamental knowledge about the components of the venom. On the basis of this knowledge, progress can be expected with regard to the two most important requirements for the development of antivenoms: greater efficacy and reduced side effects [<xref rid="B29-vetsci-11-00605" ref-type="bibr">29</xref>,<xref rid="B30-vetsci-11-00605" ref-type="bibr">30</xref>]. Recent literature data show that the application of modern proteomics has led to the characterization of the venom of 30% of snakes of the family Viperidae and 17% of snakes of the family Elapidae [<xref rid="B31-vetsci-11-00605" ref-type="bibr">31</xref>].</p><p>Our proteomic analysis of <italic toggle="yes">Vaa</italic> venom has identified the largest number of different proteins and protein families to date. To our knowledge, this is the first study to demonstrate the protective effect of an antivenom against the neurotoxic effect of the venom of <italic toggle="yes">Vaa</italic> using neuromuscular preparations of the diaphragm. We hypothesized that the neurotoxic effect of PLA2 involves the inhibition of Na<sup>+</sup>/K<sup>+</sup>-ATPase activity and showed that the venom of <italic toggle="yes">Vaa</italic> significantly inhibits this enzyme. Finally, a very strong positive correlation between the activity of the Na<sup>+</sup>/K<sup>+</sup>-ATPase and the increasing concentration of the antivenom was demonstrated.</p></sec><sec id="sec2-vetsci-11-00605"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-11-00605"><title>2.1. Chemicals and Animals</title><p>All reagents were purchased from Sigma Aldrich (St. Louis, MO, USA) and Fluka (Jerusalem, Israel).</p><p>The venoms used in this study were collected by &#x0201c;milking&#x0201d; adult <italic toggle="yes">Vaa</italic> (14 males and 6 females) originating from different parts of the Republic of Serbia. The snakes were identified by herpetologists from the Institute of Virology, Vaccines and Sera &#x0201c;Torlak&#x0201d; (Belgrade, Serbia). In this institute, the snakes are kept in a serpentarium at a controlled temperature (23&#x02013;26 &#x000b0;C) and humidity (60%). The venom obtained from them was stored at &#x02212;20 &#x000b0;C before and after lyophilization.</p><p>The antivenom &#x0201c;Viekvin&#x0201d; produced by the Institute of Virology, Vaccines and Sera &#x0201c;Torlak&#x0201d; (Belgrade, Serbia) was obtained by the immunization of healthy mares aged 5 to 10 years with a body weight of more than 600 kg. The production process of the snake antivenom &#x0201c;Viekvin&#x0201d; was described in our previous article [<xref rid="B32-vetsci-11-00605" ref-type="bibr">32</xref>].</p><p>The preparation &#x0201c;Viekvin&#x0201d; is a solution for injection or intramuscular or intravenous administration. In total, 1 mL of the preparation neutralizes not less than 100 LD<sub>50</sub> of long-nosed viper venom (<italic toggle="yes">V. ammodytes</italic>) and 50 LD<sub>50</sub> of common European adder venom (<italic toggle="yes">V. berus</italic>). Marketing Authorisation number and Date: 515-01-01036-21-001, 20 September 2021, Medicines and Medical Devices Agency of Serbia (ALIMS) (<uri xlink:href="https://torlak.rs/wp-content/uploads/2024/02/PIL-VIEKVIN-Eng.pdf">https://torlak.rs/wp-content/uploads/2024/02/PIL-VIEKVIN-Eng.pdf</uri> (accessed on 1 November 2024)).</p><p>The isolated rat diaphragm model was used to investigate the neurotoxicity of <italic toggle="yes">Vaa</italic> venom (<xref rid="sec2dot3-vetsci-11-00605" ref-type="sec">Section 2.3</xref>). Male Wistar rats weighing 200 &#x000b1; 20 g were used. The rats were kept under standard laboratory conditions, with a 12 h light/dark cycle, a room temperature of 21&#x02013;24 &#x000b0;C and <italic toggle="yes">ad libitum</italic> access to standard food and water.</p><p>The Ethics Committee of the Institute of Virology, Vaccines and Sera &#x0201c;Torlak&#x0201d;, Republic of Serbia and the Veterinary Directorate of the Ministry of Agriculture of the Republic of Serbia have approved all procedures used in this study (No. 323-07-02181/2021-05, 8 March 2021), which are in accordance with the EU Directive 2010/63/EU on the protection of animals used for scientific purposes.</p></sec><sec id="sec2dot2-vetsci-11-00605"><title>2.2. Proteomics of the Vaa Venom</title><sec id="sec2dot2dot1-vetsci-11-00605"><title>2.2.1. Preparation of Protein Fractions</title><p>Lyophilised venom (1 mg) was dissolved to an appropriate concentration in 750 &#x000b5;L of 0.1 M triethylammonium bicarbonate (TEAB, Thermo Scientific, Rockford, IL, USA). Solubilization was enhanced by vortex mixing followed by centrifugation (14,000&#x000d7; <italic toggle="yes">g</italic>, 10 min, 4 &#x000b0;C). The resulting supernatant (fraction 0) represents the total protein solution (venom). Fraction 0 was prepared in duplicate, with the first used for proteomics and the second for the preparation of the protein fractions.</p><p>The DiffPOP (differential precipitation of proteins) method was applied as previously described [<xref rid="B33-vetsci-11-00605" ref-type="bibr">33</xref>] to generate venom protein fractions (3A, 5A, 8A, 9A and 10A). In summary, fraction 0 was sequentially mixed with acidified methanol that served as a destabilizer (1% acetic acid in 90% methanol (LC-MS Cromasolv, Honeywell, Riedel-de Ha&#x000eb;n, Charlotte, NC, USA) in ultrapure water, <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). This process led to the precipitation of a subset of proteins after rigorous vortex mixing and subsequent centrifugation (14,000&#x000d7; <italic toggle="yes">g</italic>, 10 min, 4 &#x000b0;C). The supernatant containing the remaining proteins was then transferred to another low-protein binding tube, and the destabilizer was added again followed by centrifugation to obtain another protein pellet. This step was repeated a total of five times, with the volumes of added acidified methanol being 8, 25, 85, 130 and 425 &#x000b5;L. Subsequently, the collected DiffPOP protein pellets (n = 5) were washed with ice-cold acetone and centrifuged (14,000&#x000d7; <italic toggle="yes">g</italic> for 10 min at 4 &#x000b0;C). The resulting pellets were air-dried and dissolved in 0.1 M TEAB for sample preparation for proteomics.</p></sec><sec id="sec2dot2dot2-vetsci-11-00605"><title>2.2.2. Sample Preparation for Proteomics</title><p>The total protein concentrations in fractions 0, 3A, 5A, 8A, 9A and 10A were determined using a Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) according to the manufacturer&#x02019;s protocol. For the protein digestion workflow, we started with 35 &#x000b5;g proteins per fraction, adjusting the final volume to 50 &#x000b5;L per sample by adding 0.1 M TEAB. We followed the procedure described by [<xref rid="B34-vetsci-11-00605" ref-type="bibr">34</xref>] for reduction, alkylation and trypsin digestion. Initially, we reduced the proteins using a 200 mM dithiothreitol solution at 55 &#x000b0;C for 60 min, followed by alkylation with a 375 mM solution at RT for 30 min in the dark. After overnight precipitation with acetone at &#x02212;20 &#x000b0;C, the protein pellets were dissolved in 50 &#x003bc;L of 0.1 M TEAB following centrifugation. Trypsin Gold, a mass-spectrometry-grade trypsin powder from Promega, was prepared as a 1 mg/mL solution by adding 0.1 M TEAB. Trypsin solution was added to the protein aliquots at a trypsin-to-protein ratio of 1:35, and digestion was performed overnight at 37 &#x000b0;C. We then vacuum-dried peptide aliquots (10 &#x000b5;L) and prepared them for nano-LC&#x02013;MS/MS analysis.</p></sec><sec id="sec2dot2dot3-vetsci-11-00605"><title>2.2.3. Nano-Liquid Chromatography Tandem Mass Spectrometry-Based Proteomics</title><p>We performed high-resolution nano-LC&#x02013;MS/MS separation and detection of peptides on the UltiMate 3000 RSLCnano system (Thermo Fisher Scientific, Germering, Germany) coupled to the Q Exactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Before nano-LC&#x02013;MS/MS analysis, we dissolved vacuum-dried peptides in a loading solvent solution (0.1% formic acid (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) (VWR International, Darmstadt, Germany) in 2% acetonitrile (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) (Honeywell, Charlotte, NC, USA) diluted in ultrapure water (Supelco, Bellefonte, Pennsylvania, PA, USA). Peptide trapping and desalting, nano-LC&#x02013;MS/MS analysis and Top8 data-dependent acquisition (DDA) in a positive-ion mode followed our previously reported method [<xref rid="B35-vetsci-11-00605" ref-type="bibr">35</xref>]. Peptide trapping occurred for 12 min at a flow rate of 15 &#x003bc;L/min using a C18 PepMap100 (5 &#x003bc;m, 100 A, 300 &#x003bc;m &#x000d7; 5 mm) trap column and a PepMap&#x02122; RSLC C18 (50 cm &#x000d7; 75 &#x003bc;m) analytical column purchased from Thermo Fisher Scientific. Peptide separation on the analytical column utilized a linear chromatographic gradient, as described in our earlier work. During peptide separation, we used two mobile phases: mobile phase A (0.1% formic acid in water (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>)) and mobile phase B (0.1% formic acid (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) in 80% acetonitrile (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) diluted in ultrapure water). The flow rate during peptide separation was 300 nl/min. The mass spectrometer operated in a full MS scan mode with a resolution of 70.000 and an injection time set to 120 ms. We set the AGC target to 1 &#x000d7; 10<sup>6</sup> &#x000b1; 2.0 Da and applied dynamic exclusion for 30 s. HCD fragmentation was performed using collision energy (29% and 35% NCE) with a resolution of 17.500 and an AGC target of 2 &#x000d7; 10<sup>5</sup>. Peptide precursor ions without an assigned charge state and with a charge state above +7 were not fragmented.</p></sec><sec id="sec2dot2dot4-vetsci-11-00605"><title>2.2.4. Data Processing, Statistics and Bioinformatics Analysis</title><p>Raw data processing and protein identification were carried out utilizing the Proteome Discoverer software (v.2.3., Thermo Fisher Scientific, Waltham, MA, USA), employing the SEQUEST algorithm and separate database (DB) search against FASTA protein sequences for (a) <italic toggle="yes">Serpentes</italic> (snake ID number 8570) (UniProt/SwissProt release May, 2024, 361.116 sequences), (b) <italic toggle="yes">Vipera</italic> (Genus) (UniProt/SwissProt release Februry, 2024, 238562 sequences) and (c) <italic toggle="yes">V. ammodytes</italic> (UniProt/SwissProt release Februry, 2024, 90 sequences). The parameters in the Proteome Discoverer software were configured as follows: up to two missed trypsin cleavage sites were allowed, with precursor and fragment mass tolerances set at 10 ppm and 0.02 Da, respectively. The carbamidomethylation of cysteine was used as a fixed modification, while the oxidation of methionine was a dynamic modification. The false discovery rate (FDR) for peptide identification was calculated using the Percolator algorithm. Proteins were confidently identified if they had at least two unique peptides and a false discovery rate (FDR) of 1% or less.</p><p>The lists of identified master proteins (per each fraction in a total of three files) and protein groups was exported from Proteome Discoverer as a Microsoft Excel file (Excel Professional Plus 2016) and further analyzed using the PivotTable feature. The lists were specifically analyzed to identify (a) the list of master proteins/protein groups identified exclusively in fraction 0 for all databases combined, (b) the list of master proteins/protein groups identified for all fractions for each individual database separately and (c) the list of all identified protein groups for all fractions using different FASTA databases.</p><p>A Venn diagram was generated using the Venn diagram tool (<uri xlink:href="https://bioinformatics.psb.ugent.be/webtools/Venn/">https://bioinformatics.psb.ugent.be/webtools/Venn/</uri> (accessed on 1 November 2024)) by inputting protein accession numbers. This step aimed to (a) assess the protein distribution for fraction 0 using different FASTA databases, (b) evaluate the protein distribution for all fractions using <italic toggle="yes">Serpentes</italic> DB, (c) assess protein distribution for all fractions using <italic toggle="yes">Vipera</italic> DB, (d) evaluate the protein distribution for all fractions using <italic toggle="yes">V. ammodytes</italic> DB and (e) analyze the protein distribution (master proteins, two unique peptides, 1% FDR) for all fractions using different FASTA databases.</p><p>For the latter identified master proteins, if available, the alternative names, cellular component, molecular function, biological process and function in detail were copied from Uniprot/SwissProt (15&#x02013;28 May 2024).</p><p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD056495.</p></sec></sec><sec id="sec2dot3-vetsci-11-00605"><title>2.3. Examination of the Contractility of the Neuromuscular Preparations of the Diaphragm (NPD)</title><p>The Wistar rats were sacrificed under general anesthesia (ketamine 100 mg/kg + xylazine 10 mg/kg, intraperitoneal) by the dislocation of the cervical spine. Immediately after the sacrifice, the complete diaphragm of the rats was removed together with the bony base consisting of the ribs and sternum. The diaphragm hemispheres were cut into strips, with the cuts running parallel to the direction of the muscle fibers. The neuromuscular preparation of the diaphragm (NPD) was placed in a 20 mL organ bath containing Tyrode&#x02019;s solution (composition in mM: NaCl 139.9; KCl 2.7; CaCl<sub>2</sub> 1.8; MgCl<sub>2</sub> 1.04; NaHCO<sub>3</sub> 11.9; NaH<sub>2</sub>PO<sub>4</sub> 0.4 and glucose 5.5, pH 7.4) at 37 &#x000b0;C. Tyrode&#x02019;s solution was continuously aerated with a mixture of oxygen (95%) and carbon dioxide (5%). In the organ bath, the NPD is positioned in the central space between two parallel platinum electrodes connected to a BioSmart 150 stimulator (ElUnit, Serbia), which enables electrical field stimulation (EFS). The contractions were recorded in real time using the eLAB44 software (ElUnit, Serbia). The NPD is exposed to an initial tension of 1 g and waits at least 15 min until it has reached a constant basal tone and a stable amplitude of contractions. The EFS was performed with tetanic pulses, a series of &#x0201c;packages&#x0201d; with 5 stimulations every 30 s. The pauses between the &#x0201c;packages&#x0201d; were 5, 15 or 30 min, depending on the work protocol. The following parameters were used for indirect EFS: 35 Hz, 20 &#x000b5;s, 2 s and 15 V; and the following were used for direct EFS: 100 Hz, 500 &#x000b5;s, 2 s and 50 V. The maximum contraction values reached were measured and the possible occurrence of tetanic fade after the administration of the venom was monitored. The non-depolarizing neuromuscular blocker pancuronium (in phosphate buffered saline&#x02014;PBS) was used to prove that the indirect EFS technique induces muscle contractions only via the mediation of the neuromuscular synapse. Pancuronium was administered at a concentration of 1 &#x003bc;M during contractions of the NPD without the presence of the venom and at a concentration of 3 &#x003bc;M during contractions under the influence of the venom.</p><p>In the initial phase of the study, different concentrations of the crude venom were administered and the contractility of the NPD was monitored as a function of time. For these tests, a stock solution of the crude venom was used at a concentration of 20 mg/mL PBS, from which a series of dilutions were prepared (from 0.10 to 50 &#x000b5;g/mL). In the final tests, a concentration of 35 &#x000b5;g/mL of crude venom was used as the appropriate concentration as it resulted in an almost complete inhibition of NPD contractility (over 90% inhibition compared to the control). The protective effect of antivenom on the contractility of NPD was investigated using venom/antivenom mixtures at different mass ratios (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>): 1:2, 1:10 and 1:20. The mixtures were pre-incubated for 30 min at a constant temperature of 37 &#x000b0;C [<xref rid="B36-vetsci-11-00605" ref-type="bibr">36</xref>]. The protein concentration of the antivenom used for these tests was 100 mg/mL. In order to compare the protective effects of different venom/antivenom mixtures (1:2; 1:10; 1:20), the mean effective time (ET<sub>50</sub>) was used. Logarithmic functions of time (log<sub>10</sub>, minutes), the normalization of effects (% of control NPD contractions) and non-linear regression were used to calculate the ET<sub>50</sub> value. After the completion of the NPD contractility tests, AChE and Na<sup>+</sup>/K<sup>+</sup>-ATPase activity was determined in the same preparations.</p></sec><sec id="sec2dot4-vetsci-11-00605"><title>2.4. Determination of the Activity of Acetylcholinesterase (AChE) and Sodium/Potassium ATPase (Na<sup>+</sup>/K<sup>+</sup>-ATPase) in the NPD</title><p>The diaphragmatic tissue samples were homogenized in a buffer containing 50 mM Tris HCl pH 7.4; 20 mM EDTA, 1 M NaCl and 1% Triton-X100 according to the method of Krummer et al. [<xref rid="B37-vetsci-11-00605" ref-type="bibr">37</xref>]. An Ultra Turrax homogenizer (Janke and Kunkel IKA Works GmbH &#x00026; Co. KG Staufen, Staufen/Germany) was used for homogenization. The ratio of tissue-to-buffer was 1:5 (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), and homogenization was performed on ice. The homogenate was centrifuged at 20,817&#x000d7; <italic toggle="yes">g</italic> at +4 &#x000b0;C. The supernatant was then poured off, stored at &#x02212;20 &#x000b0;C and used for further analyses.</p><p>AChE activity in the diaphragm was determined using acetylthiocholine iodide as the substrate according to Ellman et al. [<xref rid="B38-vetsci-11-00605" ref-type="bibr">38</xref>]. The reaction was monitored spectrophotometrically over a period of 5 min at 412 nm. The results are expressed in units per milligram protein of the diaphragm (U/mg P). The protein concentration was determined according to the method of Lowry et al. [<xref rid="B39-vetsci-11-00605" ref-type="bibr">39</xref>], using bovine serum albumin (BSA) as a standard.</p><p>The determination of Na<sup>+</sup>/K<sup>+</sup>-ATPase activity in the diaphragm was carried out according to the method of Pari and Murugavel [<xref rid="B40-vetsci-11-00605" ref-type="bibr">40</xref>]. The supernatant of the diaphragm was added to a reaction mixture containing 50 mM Tris HCl, 5 mM MgCl<sub>2</sub>, 100 mM NaCl, 20 mM KCl and pH 7.5 and the mixture was then incubated at 37 &#x000b0;C in the presence of 10 mM ATP. The reaction was stopped by adding cold trichloroacetic acid (TCA) solution. After protein precipitation and centrifugation at 10,621&#x000d7; <italic toggle="yes">g</italic>, the concentration of released inorganic phosphorus in the supernatant was determined by incubating the mixture with a solution of (NH<sub>4</sub>)<sub>6</sub>MO<sub>7</sub>O<sub>24</sub> and vitamin C. The absorbance was then measured at 620 nm. The enzyme activity was expressed by the concentration of inorganic phosphorus in U/mg P, and a 3 mM solution of primary potassium phosphate was used as a standard.</p></sec><sec id="sec2dot5-vetsci-11-00605"><title>2.5. Activity of Venom Phospholipase A2 (PLA2) and Neutralization by Antivenom</title><p>The activity of PLA2 of the venom of <italic toggle="yes">Vaa</italic> was determined according to the modified methods of Tan and Tan [<xref rid="B41-vetsci-11-00605" ref-type="bibr">41</xref>]. A fresh solution of the substrate was prepared by mixing egg yolk (380 g) with 18.1 mM sodium deoxycholate and 8 mM CaCl<sub>2</sub> at a ratio of 1:1:1 (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) overnight at room temperature. The pH was adjusted to 8.1 with 0.15 M NaOH. The venom solution was added to a substrate at a concentration range of 0.05 to 1 mg/mL, and the pH change was observed for 60 s. All measurements were carried out in triplicate (n = 3). To test the neutralization of PLA2 by antivenom, a 1 mg/mL solution of the venom was used. Antivenom concentrations from 5 to 50 mg/mL were tested. The test was performed after the incubation of the venom/antivenom mixture at 37 &#x000b0;C for 30 min. The results are expressed as pH change per unit time (&#x00394;pH/min).</p></sec><sec id="sec2dot6-vetsci-11-00605"><title>2.6. Statistical Analysis</title><p>The data obtained were processed using GraphPad Prism 8.00 statistical software (GraphPad Software Inc., San Diego, CA, USA). The statistical analysis of the results on the neurotoxicity of the venom was performed using a one-way ANOVA followed by Tukey&#x02019;s Multiple Comparison Test. Values <italic toggle="yes">p</italic> &#x0003c; 0.05 were considered significant. All experimental results are expressed as the mean &#x000b1; SD. Correlation was tested using Pearson&#x02019;s correlation analysis (r).</p></sec></sec><sec sec-type="results" id="sec3-vetsci-11-00605"><title>3. Results</title><sec id="sec3dot1-vetsci-11-00605"><title>3.1. Proteomics of the Vaa Venom</title><p>The numbers of identified master proteins (FDR &#x0003c; 1% and 2 unique peptides) are presented as Venn diagrams in <xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>. The total ion chromatograms (TIC) for the complete venom, fraction 0 and for the DiffPOP protein fractions 3A, 5A, 8A, 9A, 10A are shown in <xref rid="app1-vetsci-11-00605" ref-type="app">Figure S1</xref>.</p><p>In total, 79 master proteins were identified (with 1% FDR and two unique peptides) in the complete <italic toggle="yes">Vaa</italic> venom (fraction 0, <xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>A). The highest number of identified master proteins was reported for the proteomics approach which included the application of <italic toggle="yes">Serpentes</italic> DB (52 proteins), followed by <italic toggle="yes">Vipera ammodytes</italic> and <italic toggle="yes">Vipera</italic> DB (both 34 proteins, <xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>A). Proteins identified by a comparison to <italic toggle="yes">Serpentes</italic> DB showed an owerlap with the other two lists of identified proteins, while a higher overlap can be observed with <italic toggle="yes">Vipera ammodytes</italic> DB (20 proteins, <xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>A). The lists of identified proteins presented in <xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>A, including the identification number, the description of the protein (name, organism in which it occurs), the molecular mass and the isoelectric point (pI), can be found in <xref rid="app1-vetsci-11-00605" ref-type="app">Supplement S1 (Table S1)</xref>. The number of master proteins in all analyzed <italic toggle="yes">Vaa</italic> fractions (3A, 5A, 8A, 9A and 10A, including complete <italic toggle="yes">Vaa</italic> venom, fraction 0) is shown in <xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>B&#x02013;D, depending on which protein FASTA databases (DB) were used for protein identification. The total number of identified (1% FDR and 2 unique peptides) venom proteins in all fractions varied from 124 when <italic toggle="yes">Serpentes</italic> DB (<xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>B) was used to 60 when <italic toggle="yes">Vipera</italic> DB (<xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>C) was used and to 44 when <italic toggle="yes">Vipera ammodytes</italic> DB (<xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>D) was used. A detailed list of identified master proteins presented in <xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>B&#x02013;D can be found in <xref rid="app1-vetsci-11-00605" ref-type="app">Supplement S2 (Tables S2&#x02013;S4)</xref>. The number of identified master proteins (2 unique peptides, 1% FDR) in all <italic toggle="yes">Vaa</italic> fractions (0, 3A, 5A, 8A, 9A and 10A) when different protein FASTA databases were used in the analysis is presented in <xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>E. The Veen diagram shows the highest number of master proteins identified when Serpentes DB was applied in the analysis (in total, 124 proteins), followed by Vipera DB with 60 proteins and Vipera ammodytes DB with 44 proteins (<xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>E). A higher degree of overlaps can be observed between identified lists of proteins for Serpentes DB with both DBs, Vipera and Vipera ammodytes (<xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>E).</p><p>The list of corresponding protein groups identified in all fractions (including complete venom) for individual databases is provided in <xref rid="app1-vetsci-11-00605" ref-type="app">Supplement S3 (Tables S5&#x02013;S8)</xref>. The numbers of identified protein groups followed the trends presented for identified master proteins. Specifically, Serpentes DB provided 52, and Vipera and Vipera ammodytes DB both provided 34 identified protein groups for complete venom (fraction 0) (<xref rid="app1-vetsci-11-00605" ref-type="app">Table S5</xref>). Serpentes DB provided 118, Vipera DB provided 70 and Vipera ammodytes provided 44 identified protein groups for all analyzed fractions, including total venom (<xref rid="app1-vetsci-11-00605" ref-type="app">Table S9</xref>).</p><p>The total number of master proteins identified (with 1% FDR and two unique peptides, combined for all 3 FASTA DB) in the Vaa venom in our study is 159 (<xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>E), originating from 26 protein families (<xref rid="app1-vetsci-11-00605" ref-type="app">Supplement S5, Table S10</xref>). The proteins of the Vaa venom identified in our study belong to four families of enzymatic proteins: (1) Snake venom serine proteases (SvSPs), (2) L-amino acid oxidases (LAAOs), (3) Snake venom metalloproteinases (SvMPs), (4) Secretory phospholipases A2 (sPLA2s) and (5) non-enzymatic families: (1) Cysteine-rich secretory proteins (CRISPs), (2) Snake C-type lectin-like proteins (Snaclecs), (3) Venom nerve growth factors (VNGFs), (4) Vascular endothelial growth factors (VEGFs) and (5) Kunitz-type serine protease inhibitors (SPIs). Regarding the quantitative representation of the enzymes, SvMPs, sPLA2s, LAAOs and SvSPs dominate in the Vaa venom with a proportion of 53.5%. The relative abundance (%) of protein groups in the Vaa venom is shown in <xref rid="vetsci-11-00605-f003" ref-type="fig">Figure 3</xref>.</p><p>The bioinformatic analysis identified alternative names, cellular components, molecular functions, biological processes and functions for the main proteins detected (<xref rid="app1-vetsci-11-00605" ref-type="app">Supplement S5, Table S10</xref>).</p><p>The proteomic analysis in our study revealed the presence of 22 isoforms of serine proteases (or serine endopeptidases&#x02014;SvSPs) with molecular masses ranging from 25.1 to 38.0 kDa and pI values ranging from 5.31 to 9.19 (<xref rid="app1-vetsci-11-00605" ref-type="app">Supplement S2, Table S2</xref>). The relative abundance of SvSP in the venom is 11.60%.</p><p>The phospholipases (PL) of <italic toggle="yes">Vaa</italic> venom belong to group A and subgroup 2 (PLA2). Proteomic analyses have shown that the venom of <italic toggle="yes">Vaa</italic> contains several different PLA2, of which the neurotoxic Ammodytoxins (Atxs) are present in three different isoforms: AtxA, AtxB and AtxC. The venom of <italic toggle="yes">Vaa</italic> contains all three isoforms of this enzyme, which have the same molecular mass but different pI values and relative abundances in the composition of the venom (<xref rid="vetsci-11-00605-t001" ref-type="table">Table 1</xref>). Ammodytin L (AtnL) is a structural analog of AtxA and is enzymatically inactive but shows myotoxic and cardiotoxic effects. In addition, <italic toggle="yes">Vaa</italic> venom also contains two enzymatically active but non-toxic Ammodytins I (AtnsI): AtnI1 and AtnI2 (<xref rid="vetsci-11-00605-t001" ref-type="table">Table 1</xref>). The relative abundance of PLA2s in <italic toggle="yes">Vaa</italic> venom is 11.60%, of which 4.35% are neurotoxic Ammodytoxins (A, B, C), while the remaining 7.25% are Ammodytins (Atns), which have no neurotoxic effect.</p><p><italic toggle="yes">Vaa</italic> venom is rich in metalloproteinases (SvMPs), which account for 20.30% of venom protein groups (<xref rid="vetsci-11-00605-f003" ref-type="fig">Figure 3</xref>B). Based on their structure, snake venom metalloproteinases are divided into three classes: P-I, P-II and P-III. We have detected the presence of 53 isoforms of metalloproteinases with Uniport DB <italic toggle="yes">Serpentes</italic> (<xref rid="app1-vetsci-11-00605" ref-type="app">Supplement S2, Table S2</xref>). The molecular masses of these proteins range from 13.9 to 70.5 kDa, with pI values between 4.98 and 7.75. Of these 53 isoforms, 3 isoforms belong to PII MPII (Mw 53.0&#x02013;53.4 kDa, pI 5.38&#x02013;5.5), 4 belong to PIII MPIII (Mw 68.3&#x02013;69.2 kDa, pI 5.30&#x02013;6.25), 11 belong to the Zn<sup>2+</sup>-metalloproteinases disintegrin-like protein H4 subunit A (Mw 46.8&#x02013;69.1 kDa, pI 4.88&#x02013;6.38), 1 isoform is a Zn<sup>2+</sup>-metalloproteinase disintegrin-like ammodytagin (Mw 19.9 kDa, pI 5.15) and 34 isoforms are metalloproteinases (SvMP) (13.9&#x02013;70.5 kDa, pI 4.98&#x02013;7.75). Zn<sup>2+</sup>-dependent proteins (Zn-finger proteins) are also present in the <italic toggle="yes">Vaa</italic> venom. These are proteins with different molecular masses between 59.4 and 78.5 kDa and a pI value between 6.67 and 9.57. We have shown that there are 15 isoforms of the enzyme L-amino acid oxidase (LAAO) in <italic toggle="yes">Vaa</italic> venom: 1 isoform with a low molecular weight (Mw 10.3 kDa; pI 5.21), 2 isoforms with Mw 35.0&#x02013;46.3 kDa and pI 7.72&#x02013;8.76 and 12 isoforms with higher molecular weights (Mw 56.5&#x02013;58.6 kDa; pI 6.49&#x02013;8.54). The relative abundance of LAAO in the venom is 5.80%. Glutaminyl-peptide cyclotransferase (GPAT) is a protein with a molecular weight of 42.2 kDa and a pI value of 8.1. This enzyme is present in small amounts in <italic toggle="yes">Vaa</italic> venom, with a relative abundance of 1.40%.</p><p>Low-abundance enzymes in <italic toggle="yes">Vaa</italic> venom include thrombin-like enzymes (TLEs), which were identified with a relative abundance of 1.40%. Three isoforms were detected: two acidic (2.9 kDa; pI 4.28 and 25.4 kDa; pI 5.12) and one basic (27 kDa; pI 8.34). These are serine proteases that mimic thrombin activity and are found in the venoms of many snakes, particularly those of the Viperidae and Crotalidae families. Other enzymes with a low abundance include 5&#x02032;-nucleotidase (Mw 45 kDa; pI 6.9) with a relative abundance of 1.40%, two isoforms of phosphodiesterase (PD) (Mw 91.7&#x02013;96.1 kDa; pI 7.25&#x02013;8.07) with a relative abundance of 1.40%, &#x003b2;-fibrinogenase (Mw 28.3 kDa; pI 7.34), coagulation factor-X activating enzyme heavy chain (Mw 68.7 kDa; pI 6.15 and 69.6 kDa; pI 6.9) with a relative abundance of 1.40% and phospholipase B (Mw 64.3; pI 8.5) with a relative abundance of 2.90% (<xref rid="vetsci-11-00605-f003" ref-type="fig">Figure 3</xref>B).</p><p>Among the non-enzymatic components of <italic toggle="yes">Vaa</italic> venom, we identified Snake C-type lectin-like proteins (Snaclecs) as the most abundant non-enzymatic proteins with a prevalence of 17.40%. Proteomic analysis revealed 24 isoforms of this protein, of which 14 belong to the C-type lectins (Mw 11.8&#x02013;18.7 kDa; pI 5.59&#x02013;8.12) and 10 belong to the Snaclecs (Mw 12.1&#x02013;18.1 kDa; pI 4.68&#x02013;8.19). Disintegrins (Dis) are another family of non-enzymatic proteins in <italic toggle="yes">Vaa</italic> venom. They are common components of the venoms of Viperidae and act as integrin antagonists. Their relative abundance in <italic toggle="yes">Vaa</italic> venom is 8.70%, and we have identified 13 isoforms of this protein: 1 isoform (36.8 kDa; pI 5.03), 5 isoforms (11.5&#x02013;14.0 kDa; pI 6.87&#x02013;8.56) and 7 isoforms with very-small-molecular-weight proteins (7.0&#x02013;7.7 kDa; pI 5.2&#x02013;8.19). Cysteine-rich secretory proteins (CRISP) have also been identified. These are low-molecular-weight proteins, of which four isoforms (24.7&#x02013;26.6 kDa; pI 5.96&#x02013;7.46) with a relative abundance of 2.90% appear in the <italic toggle="yes">Vaa</italic> venom. Venom nerve growth factor (VNGF) (Mw 27.3 kDa; pI 8.29) was identified with an abundance of 4.30%. In addition, vascular endothelial growth factor (VEGF) (Mw 16.2 kDa; pI 5.3) and the two isoforms of VEGF toxin vammin (Mw 22.3&#x02013;22.5 kDa; pI 7.83&#x02013;7.96) were found with a relative abundance of 1.40% in the <italic toggle="yes">Vaa</italic> venom.</p><p>The following peptides were identified in <italic toggle="yes">Vaa</italic> venom: serine protease inhibitors&#x02014;Kunitz/SPi (Mw 10.3 kDa; pI 8.7) and four isoforms of Kunitz/BPTI (Mw 9.8&#x02013;10.6 kDa; pI 8.27&#x02013;8.92) with a relative abundance of 5.90%; The cystatin belong to a family of cysteine protease inhibitors (Mw 12.7 kDa; pI 7.81); metalloproteinase inhibitors (MPi-3) (Mw 22.9 kDa; pI 9.06), phospholipase A2 inhibitor (Mw 22.2 kDa; pI 6.42) and endogenous tripeptide (MPi-5) (Mw 15 kDa; pI 8.06). The identified trace components include natriuretic peptide (Mw 2&#x02013;3 kDa).</p><p>The proteins present in <italic toggle="yes">Vaa</italic> venom include glutathione peroxidase, lipase, deoxyribonuclease, aminopeptidase, endonuclease, amine oxidase, hyaluronidase, thioredoxin, transferrin, serum albumin-like protein and other proteins (<xref rid="app1-vetsci-11-00605" ref-type="app">Supplement S2, Table S2</xref>).</p></sec><sec id="sec3dot2-vetsci-11-00605"><title>3.2. The Effects of Vaa Venom on the NPD Contractility and Protective Effect of Antivenom</title><p>In order to validate the diaphragm contractility testing methodology, a series of control NPD contractions were first performed as a function of time (in minutes). <xref rid="vetsci-11-00605-f004" ref-type="fig">Figure 4</xref> shows a representative recording of NPD contractions induced by EFS in the absence of venom.</p><p>The mean value of NPD contractions in the first two control &#x0201c;packages&#x0201d; (C<sub>1</sub> and C<sub>2</sub>) is 2.88 &#x000b1; 0.13 g. After the administration of 1 &#x003bc;M pancuronium, the contractions of the NPD decreased to 51.20% of the mean value of the contractions of the control &#x0201c;packages&#x0201d; C<sub>1</sub> and C<sub>2</sub>. The neuromuscular blockade by pancuronium was reversible, and after its washout from the organ bath, the contractions normalized and reached the following values: the W<sub>1</sub> &#x0201c;package&#x0201d; 93.02% and the W<sub>2</sub> &#x0201c;package&#x0201d; 87.25% of the control contractions C<sub>1</sub> and C<sub>2</sub>. The first 5 &#x0201c;packages&#x0201d; (C<sub>1</sub>, C<sub>2</sub>, pancuronium 1 &#x003bc;M, W<sub>1</sub>, W<sub>2</sub>) confirm that NPD contractions are induced by indirect EFS. Over the next 10 &#x0201c;packages&#x0201d; in a 300 min period, contractions were stable as a function of time, and 5 contractions within each &#x0201c;package&#x0201d; were uniform in the amplitude of contractions, i.e., standard deviations (&#x000b1;SD).</p><p>In the next part, a series of NPD contractions were performed under the influence of the venom as a function of time. A representative recording of EFS-induced NPD contractions under the influence of the venom is shown in <xref rid="vetsci-11-00605-f005" ref-type="fig">Figure 5</xref>.</p><p>The mean value of the NPD contractions in the first two control &#x0201c;packages&#x0201d; of contractions (C<sub>1</sub> and C<sub>2</sub>) is 3.42 &#x000b1; 0.08 g. Pancuronium at a concentration three times higher than in the previous series (3 &#x003bc;M) led to an almost complete blockade of NPD contractions (5.62% of control &#x0201c;packages&#x0201d; C<sub>1</sub> and C<sub>2</sub>). The effect of the neuromuscular blockade of pancuronium was also reversible, because after the pancuronium had been washed out of the organ bath, the contractions of the &#x0201c;packages&#x0201d; W<sub>1</sub> and W<sub>2</sub> amounted to 97.63% and 101.14% of the control contractions, respectively. The next twelve &#x0201c;packages&#x0201d; show NPD contractions induced by indirect EFS. Under the influence of the venom, the &#x0201c;packages&#x0201d; of NPD contractions differed from each other with high statistical significance (<italic toggle="yes">p</italic> &#x0003c; 0.001) up to the 120th minute of exsposition. From the 120th to 180th minute, each subsequent NPD &#x0201c;package&#x0201d; of contractions did not differ statistically from the previous one (<italic toggle="yes">p</italic> &#x0003e; 0.05). However, a statistically significant difference was observed between the 120th and 180th minute (<italic toggle="yes">p</italic> &#x0003c; 0.001) and between the 135th and 180th minute (<italic toggle="yes">p</italic> &#x0003c; 0.01). At the end of this series, 2 &#x0201c;packages&#x0201d; of NPD contractions were induced with direct EFS parameters. The mean values of the contractions are similar to those of the control and are 95.82% (&#x0201c;package&#x0201d; at 195 min) and 94.29% (&#x0201c;package&#x0201d; at 210 min) with respect to the control &#x0201c;packages&#x0201d; C<sub>1</sub> and C<sub>2</sub>.</p><p><xref rid="vetsci-11-00605-t002" ref-type="table">Table 2</xref> gives an overview of the percentage decrease in diaphragm contractility over time under the influence of the venom and all three tested venom/antivenom mixtures (1:2; 1:10; 1:20).</p><p>In the following three series of tests, the protective effect of the antivenom was evaluated with regard to the prevention of the progressive decline in diaphragmatic contractility under the effect of the venom. In this and the next two series of NPD contractions, we used a slightly modified protocol. To objectively evaluate the protective effect of the antivenom, we tested the stability of the NPD contractions prior to the administration of the venom/antivenom mixtures with five control &#x0201c;packages&#x0201d; (C<sub>1</sub>&#x02013;C<sub>5</sub>) for 60 min.</p><p><xref rid="app1-vetsci-11-00605" ref-type="app">Figure S2</xref> shows a representative recording of EFS-induced NPD contractions under the influence of the mixture of venom/antivenom at a ratio of 1:2. The mean value of the NPD contractions in the first five control &#x0201c;packages&#x0201d; (C<sub>1</sub>&#x02013;C<sub>5</sub>) is 2.14 &#x000b1; 0.08 g. The next twelve &#x0201c;packages&#x0201d; show NPD contractions induced by indirect EFS. Under the influence of the venom/antivenom mixture at a ratio of 1:2, the &#x0201c;package&#x0201d; of NPD contractions after 15 min of exposure was not statistically significantly different (<italic toggle="yes">p</italic> &#x0003e; 0.05) from the control contractions. From the 15th to the 75th minute, each subsequent &#x0201c;package&#x0201d; of NPD contractions was statistically significantly different from the previous one (<italic toggle="yes">p</italic> &#x0003c; 0.01), while from the 75th to the 180th minute, each 30 min decrease in NPD contractions reached statistical significance (<italic toggle="yes">p</italic> &#x0003c; 0.01). The mean values of the &#x0201c;package&#x0201d; contractions (%) compared to the control contractions are listed in <xref rid="vetsci-11-00605-t002" ref-type="table">Table 2</xref>. The last two &#x0201c;packages&#x0201d; of NPD contractions were induced by direct EFS, and their mean values were 127.19% (&#x0201c;package&#x0201d; at 195 min) and 123.88% (&#x0201c;package&#x0201d; at 210 min) compared to the mean value of the five control &#x0201c;packages&#x0201d;.</p><p>In the penultimate test series, the mixture of venom/antivenom was used at a ratio of 1:10 (<xref rid="app1-vetsci-11-00605" ref-type="app">Figure S3</xref>). The mean value of the NPD contractions in the first five control &#x0201c;packages&#x0201d; (C<sub>1</sub>&#x02013;C<sub>5</sub>) is 5.15 &#x000b1; 0.25 g. The next twelve &#x0201c;packages&#x0201d; show NPD contractions induced by indirect EFS. Under the influence of the venom/antivenom mixture at a ratio of 1:10, the &#x0201c;package&#x0201d; of NPD contractions after 15 min of exposure was not statistically significantly different (<italic toggle="yes">p</italic> &#x0003e; 0.05) from the control contractions. From the 15th to the 45th minute, each subsequent &#x0201c;package&#x0201d; of NPD contractions was statistically significantly different from the previous one (<italic toggle="yes">p</italic> &#x0003c; 0.001). From the 45th to 105th minute, each subsequent &#x0201c;package&#x0201d; of NPD contractions did not differ statistically from the previous one (<italic toggle="yes">p</italic> &#x0003e; 0.05), while a statistically significant difference was observed between the 105th and 135th minute (<italic toggle="yes">p</italic> &#x0003c; 0.05). From the 135th to the 180th minute, each subsequent &#x0201c;package&#x0201d; of NPD contractions was statistically significantly different from the previous one (<italic toggle="yes">p</italic> &#x0003c; 0.01). The mean values of the &#x0201c;package&#x0201d; contractions (%) compared to the control contractions are listed in <xref rid="vetsci-11-00605-t002" ref-type="table">Table 2</xref>. The last two &#x0201c;packages&#x0201d; of NPD contractions were induced by direct EFS, and their mean values were 122.30% (&#x0201c;package&#x0201d; at 195 min) and 124.90% (&#x0201c;package&#x0201d; at 210 min) compared to the mean value of the five control &#x0201c;packages&#x0201d;.</p><p>In the final phase of the study, the mixture of venom/antivenom was used at a ratio of 1:20 (<xref rid="app1-vetsci-11-00605" ref-type="app">Figure S4</xref>). The mean value of the NPD contractions in the first five control &#x0201c;packages&#x0201d; (C<sub>1</sub>&#x02013;C<sub>5</sub>) is 4.02 &#x000b1; 0.11 g. Since we found in this test series that the contractions of the NPD under the influence of the venom/antivenom mixture at a mass ratio of 1:20 did not fall below 50% of the control values even after twelve &#x0201c;packages&#x0201d; of stimulation, we applied fifteen &#x0201c;packages&#x0201d; of stimulation in the last series. Under the influence of the venom/antivenom mixture, the &#x0201c;packages&#x0201d; of the NPD contractions did not differ statistically significantly (<italic toggle="yes">p</italic> &#x0003e; 0.05) from the contractions of the control up to the 60th minute of exposition. From the 15th to the 90th minute, the &#x0201c;packages&#x0201d; of NPD contractions did not differ statistically significantly from each other (<italic toggle="yes">p</italic> &#x0003e; 0.05). From the 90th to the 225th minute, each subsequent &#x0201c;packages&#x0201d; of NPD contractions was not statistically significantly different from the previous one (<italic toggle="yes">p</italic> &#x0003e; 0.05). The first statistically significant difference was found between the &#x0201c;packages&#x0201d; at the 90th and 195th minutes (<italic toggle="yes">p</italic> &#x0003c; 0.01), while the statistical significance between the 90th and 225th minutes was <italic toggle="yes">p</italic> &#x0003c; 0.001. The mean values of the &#x0201c;package&#x0201d; contractions (%) compared to the control contractions are listed in <xref rid="vetsci-11-00605-t002" ref-type="table">Table 2</xref>. It can be observed that even after 15 &#x0201c;packages&#x0201d; for 225 min, the mean value of the NPD contractions was above 50% of the control contractions (56.90% compared to the control contractions). As in the previous test series, two &#x0201c;packages&#x0201d; of contractions were induced by direct EFS at the end of this last series. Their mean values of NPD contractions are higher than those of the control and amount to 114.41% (&#x0201c;package&#x0201d; at 240 min) and 111.33% (&#x0201c;package&#x0201d; at 255 min) compared to the five &#x0201c;packages&#x0201d; of the control.</p><p>Logarithmic functions of time (log<sub>10</sub>, minutes) and normalization of effects (% of control NPD contractions) were used to generate sigmoidal curves of reduction in NPD contractions under the influence of venom and venom/antivenom mixtures at different mass ratios (1:2; 1:10; 1:20) (<xref rid="vetsci-11-00605-f006" ref-type="fig">Figure 6</xref>).</p><p>Non-linear regression was used to calculate the mean effective time (ET<sub>50</sub>) for which NPD contractions are reduced to 50% of control values after the administration of venom and venom/antivenom mixtures at different mass ratios (<xref rid="vetsci-11-00605-t003" ref-type="table">Table 3</xref>).</p><p>A statistically significant difference was demonstrated between the ET<sub>50</sub> for the venom and the venom/antivenom mixtures at the ratios of 1:2, 1:10 and 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) at the significance level of <italic toggle="yes">p</italic> &#x0003c; 0.05, <italic toggle="yes">p</italic> &#x0003c; 0.001 and <italic toggle="yes">p</italic> &#x0003c; 0.001, respectively. There is also a highly significant difference (<italic toggle="yes">p</italic> &#x0003c; 0.001) between the ED<sub>50</sub> for different mass ratios of venom/antivenom (<xref rid="vetsci-11-00605-f007" ref-type="fig">Figure 7</xref>).</p><p>As part of the investigation of NPD contractions, we examined the possible occurrence of a tetanic fade after the administration of venom and a 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) venom/antivenom mixture. The magnified peaks of the NPD contractions are shown in <xref rid="vetsci-11-00605-f008" ref-type="fig">Figure 8</xref>.</p><p>In contrast to pancuronium, which leads to a tetanic fade (<xref rid="vetsci-11-00605-f008" ref-type="fig">Figure 8</xref>B, black arrows), the occurrence of a tetanic fade was not recorded in NPD contractions under the influence of venom (<xref rid="vetsci-11-00605-f008" ref-type="fig">Figure 8</xref>C, white arrows) and the mixture of venom/antivenom at a ratio of 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) (<xref rid="vetsci-11-00605-f008" ref-type="fig">Figure 8</xref>D, white arrows).</p></sec><sec id="sec3dot3-vetsci-11-00605"><title>3.3. The Effects of Vaa Venom on the Activity of AChE and Na<sup>+</sup>/K<sup>+</sup>-ATPase in the NPD</title><p>No statistically significant difference (<italic toggle="yes">p</italic> &#x0003e; 0.05) was found in AChE enzyme activity in NPD under the influence of venom and venom/antivenom mixtures at all mass ratios tested compared to the control group (<xref rid="vetsci-11-00605-f009" ref-type="fig">Figure 9</xref>).</p><p>The differences in Na<sup>+</sup>/K<sup>+</sup>-ATPase activity in all NPD samples analyzed are shown in <xref rid="vetsci-11-00605-f010" ref-type="fig">Figure 10</xref>.</p><p>The results show that <italic toggle="yes">Vaa</italic> venom inhibits the activity of Na<sup>+</sup>/K<sup>+</sup>-ATPase highly significantly (<italic toggle="yes">p</italic> &#x0003c; 0.001) compared to the control (51.79% inhibition). With an increase in the mass fraction of the antivenom, the enzymatic activity of the Na<sup>+</sup>/K<sup>+</sup>-ATPase increases in comparison to the activity under the influence of the venom. The 1:2 and 1:10 venom/antivenom mixtures statistically significantly (<italic toggle="yes">p</italic> &#x0003c; 0.01) restore the activity of Na<sup>+</sup>/K<sup>+</sup>-ATPase compared to the effect of the venom. However, the enzyme activity remains highly significantly (<italic toggle="yes">p</italic> &#x0003c; 0.001) lower than the control value and after the application of the 1:10 mixture. After the application of the mixture at a ratio of 1:20, there is no longer a statistically significant difference in the activity of the Na<sup>+</sup>/K<sup>+</sup>-ATPase compared to the control (<italic toggle="yes">p</italic> &#x0003e; 0.05). We tested the correlation between the activity of Na<sup>+</sup>/K<sup>+</sup>-ATPase in the NPD after applying different ratios of venom/antivenom: 1:2, 1:10 and 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>). The Pearson correlation showed a very strong positive correlation (r = 0.9150, *** <italic toggle="yes">p</italic> &#x0003c; 0.001) between the activity of the Na<sup>+</sup>/K<sup>+</sup>-ATPase and the increasing concentration of the antivenom.</p></sec><sec id="sec3dot4-vetsci-11-00605"><title>3.4. The Examination of PLA2 Activity in Vaa Venom and Neutralization by Antivenom</title><p>Under in vitro conditions, we investigated the activity of PLA2 in venom and the neutralization of its activity by antivenom based on the &#x00394;pH over time using an egg yolk suspension as a substrate. The results are shown in <xref rid="vetsci-11-00605-f011" ref-type="fig">Figure 11</xref>.</p><p>With an increase in the venom concentration in the substrate, there is an increase in &#x00394;pH/min, which indicates an increase in PLA2 activity (<xref rid="vetsci-11-00605-f011" ref-type="fig">Figure 11</xref>A). The addition of increasing concentrations of antivenom at a constant venom concentration (1 mg/mL) led to a decrease in the value of &#x00394;pH/min (<xref rid="vetsci-11-00605-f011" ref-type="fig">Figure 11</xref>B). This indicates a decrease in PLA2 activity, i.e., the neutralizing effect of the antivenom. Our results show that the activity of PLA2 in 1 mg of crude <italic toggle="yes">Vaa</italic> venom is completely neutralized by 18.12 mg of antivenom.</p></sec></sec><sec sec-type="discussion" id="sec4-vetsci-11-00605"><title>4. Discussion</title><p>Research into the composition of snake venom requires a multidisciplinary approach. Omics technologies, i.e., genomics, transcriptomics and proteomics, have recently played an increasingly important role in the field of venom research [<xref rid="B43-vetsci-11-00605" ref-type="bibr">43</xref>,<xref rid="B44-vetsci-11-00605" ref-type="bibr">44</xref>]. As a result of the application of these technologies, the number of new studies on the composition of snake venoms has increased significantly in recent years [<xref rid="B45-vetsci-11-00605" ref-type="bibr">45</xref>]. However, there is still a small number of proteomic studies on the venom of <italic toggle="yes">V. ammodytes</italic>. When reviewing the PubMed database (keywords: snake venom, proteomics, <italic toggle="yes">V. ammodytes</italic>), we found that a total of 10 papers were published for the period from 2008 to 2024. Various techniques for sample preparation and analysis were used in these studies, each with their own advantages and disadvantages. The analysis of the venom of Viperidae using the &#x0201c;<italic toggle="yes">top-down</italic>&#x0201d; technique leads to an incomplete characterization of the venom due to the presence of high-molecular-weight proteins that cannot be identified. In contrast, the &#x0201c;<italic toggle="yes">bottom-up</italic>&#x0201d; technique involves the prior trypsinization of the samples. &#x0201c;<italic toggle="yes">Shotgun</italic>&#x0201d; proteomics provides a quick qualitative overview of the composition of the venom but not the determination of its quantitative composition. This method often does not allow for the detection of numerous venom isoforms or the identification of small proteins and peptides [<xref rid="B46-vetsci-11-00605" ref-type="bibr">46</xref>]. Based on the above, it can be said that the limiting factors for the comparison of the venom compositions obtained in different studies are the following: the relatively small number of studies and the use of different proteomic techniques. In our study, we used the &#x02018;bottom-up&#x02019; technique, which involves the trypsinization of the venom sample and the DiffPOP method to obtain the protein fractions of the venom (3A, 5A, 8A, 9A i 10A). In addition, data analysis against three databases (Serpentes, Vipera and Vipera ammodytes) and FDR &#x0003c; 1% provided identification of a higher number of proteins with improved confidence compared to previous studies of <italic toggle="yes">Vaa</italic> venom [<xref rid="B47-vetsci-11-00605" ref-type="bibr">47</xref>]. The results shown (<xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>) clearly indicate an increase in the number of identified proteins when all fractions (3A, 5A, 8A, 9A and 10A) and the total venom (fraction 0) were analyzed, compared to the total venom (fraction 0). Since the UniProt database for <italic toggle="yes">V. ammodytes</italic> (Vipera ammodytes DB) is significantly smaller, as presented in the <xref rid="sec2dot2dot4-vetsci-11-00605" ref-type="sec">Section 2.2.4</xref>, we analyzed the mass spectrometry results using two additional databases: Vipera genus (Vipera DB) and Serpentes (Serpentes DB) (<xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>A). As expected, the larger the DB used for searching, the higher the number of identified proteins, which we confirmed (<xref rid="vetsci-11-00605-f002" ref-type="fig">Figure 2</xref>). Given that we use corrective measures (FDR &#x0003c; 1%), the number of false positive identifications has been reduced.</p><p>The composition of snake venoms in the family Viperidae can vary considerably between genera, species and even within a single species [<xref rid="B48-vetsci-11-00605" ref-type="bibr">48</xref>]. Snake venoms are mixtures of various proteins and non-protein components (such as amino acids, amines, nucleotides, metal ions, lipids and carbohydrates)&#x02014;with or without toxic effects. Our results show that 97% of the dry mass of the <italic toggle="yes">Vaa</italic> venom consists of proteins, and proteomic analysis identified 159 different proteins originating from 26 protein families (<xref rid="app1-vetsci-11-00605" ref-type="app">Supplement S5, Table S10</xref>). It was interesting to compare our results with those of the proteomic analysis of <italic toggle="yes">Vaa</italic> venom from neighboring countries (Bulgaria, Croatia). In contrast to our results, the proteomic analysis of the venom <italic toggle="yes">Vaa</italic> from the area of Bulgaria identified 38 venom proteins originating from 9 protein families [<xref rid="B49-vetsci-11-00605" ref-type="bibr">49</xref>]. An analysis of the venom of <italic toggle="yes">Vaa</italic> from different parts of Croatia identified 57 proteins, which were classified into 16 protein families [<xref rid="B50-vetsci-11-00605" ref-type="bibr">50</xref>]. These data clearly show that there are differences in the composition of the <italic toggle="yes">Vaa</italic> venom even in geographically very close regions. In an earlier study on a proteomic analysis of the venom of <italic toggle="yes">Vaa</italic>, also from the territory of Serbia, it was reported that the number of identified proteins was 99 and the number of protein families was 9 [<xref rid="B47-vetsci-11-00605" ref-type="bibr">47</xref>].</p><p>Snake venom metalloproteinases (SvMPs) are largely responsible for the disruption of hemostasis [<xref rid="B51-vetsci-11-00605" ref-type="bibr">51</xref>]. In our study, 53 isoforms of this enzyme were detected in <italic toggle="yes">Vaa</italic> venom for the first time. Of these, 4 isoforms belonged to subclass PIII MPIII and 3 belonged isoforms to PII MPII, which is in agreement with the results of other authors [<xref rid="B50-vetsci-11-00605" ref-type="bibr">50</xref>,<xref rid="B52-vetsci-11-00605" ref-type="bibr">52</xref>,<xref rid="B53-vetsci-11-00605" ref-type="bibr">53</xref>]. Our results indicate the presence of a large amount of Zn<sup>2+</sup>-metalloproteinases disintegrin-like protein H4 subunit A (12 isoforms) and a large number of metalloproteinases (34 isoforms). Leonardi et al. [<xref rid="B50-vetsci-11-00605" ref-type="bibr">50</xref>] found that the relative abundance of SvMPS in the venom of <italic toggle="yes">Vaa</italic> from the area of Croatia is 20.40%, which is consistent with our results for the venom of <italic toggle="yes">Vaa</italic> from the area of Serbia. The SvSPs of <italic toggle="yes">Vaa</italic> venom exhibit high degrees of amino acid sequence similarity to the SvSPs of other Viperidae&#x02014;for example, in <italic toggle="yes">Macrovipera lebetina, Bitis gabonica, Daboia russelii</italic> and <italic toggle="yes">V. berus</italic> [<xref rid="B54-vetsci-11-00605" ref-type="bibr">54</xref>,<xref rid="B55-vetsci-11-00605" ref-type="bibr">55</xref>]. In our proteome analysis, 22 different serine proteases were detected, which account for 1/10 of the total proteins in <italic toggle="yes">Vaa</italic> venom (<xref rid="vetsci-11-00605-f003" ref-type="fig">Figure 3</xref>). The relative abundance of this enzyme in our study is consistent with the results of the venom of <italic toggle="yes">Vaa</italic> from the area of Croatia [<xref rid="B50-vetsci-11-00605" ref-type="bibr">50</xref>].</p><p>Snake C-type lectin-like proteins (Snaclecs) are non-enzymatic proteins that influence the following processes: thrombosis and hemostasis, cell adhesion, endocytosis and pathogen neutralization [<xref rid="B56-vetsci-11-00605" ref-type="bibr">56</xref>,<xref rid="B57-vetsci-11-00605" ref-type="bibr">57</xref>]. Our proteomic analysis has shown that Snaclecs are the most abundant non-enzymatic components in the venom of <italic toggle="yes">Vaa</italic> (<xref rid="vetsci-11-00605-f003" ref-type="fig">Figure 3</xref>). In contrast, this protein was not detected in the venom of <italic toggle="yes">Vaa</italic> from Bulgaria [<xref rid="B49-vetsci-11-00605" ref-type="bibr">49</xref>], while it was detected in the venom of <italic toggle="yes">Vaa</italic> from Croatia by transcriptome analysis with a percentage of 13.8% [<xref rid="B50-vetsci-11-00605" ref-type="bibr">50</xref>], which is a slightly lower value compared to our results.</p><p>Disintegrins (DIS) are proteins found in the venoms of various <italic toggle="yes">Vipera</italic> species that selectively block the function of integrin receptors, which play an important role in tissue homeostasis [<xref rid="B58-vetsci-11-00605" ref-type="bibr">58</xref>]. Low-molecular, cysteine-rich disintegrins strongly inhibit platelet aggregation and thus prevent blood clotting [<xref rid="B59-vetsci-11-00605" ref-type="bibr">59</xref>]. The presence of this <italic toggle="yes">Vaa</italic> venom component in our study is higher than the results of Leonardi et al. [<xref rid="B50-vetsci-11-00605" ref-type="bibr">50</xref>]. According to other authors, DIS was not detected in the venom of <italic toggle="yes">Vaa</italic> from the territory of Serbia [<xref rid="B47-vetsci-11-00605" ref-type="bibr">47</xref>].</p><p>L-amino acid oxidases (LAAOs) lead to pathological effects that are primarily due to the release of hydrogen peroxide during LAAO activity [<xref rid="B60-vetsci-11-00605" ref-type="bibr">60</xref>]. Proteomic analysis have shown that the venom of <italic toggle="yes">Vaa</italic> contains 1.6% LAAO [<xref rid="B50-vetsci-11-00605" ref-type="bibr">50</xref>], which is more than 3.5 times lower than our results.</p><p>The relative abundance of CRISPs in <italic toggle="yes">Vaa</italic> venom is determined by our proteomic analysis, and the results are consistent with the findings of Leonardi et al. [<xref rid="B50-vetsci-11-00605" ref-type="bibr">50</xref>].</p><p>One of the potential hemotoxins found in a small percentage in the venom of <italic toggle="yes">Vaa</italic> is phosphodiesterase (PD). In addition, we have detected components that are less represented in the venom, such as venom nerve growth factors (VNGFs), coagulation factor X, cystatin, &#x003b2;-fibrinogenase, &#x003b1;-fibrinogenase, peroxiredoxin, hyaluronidase, aminopeptidase, renin, TATA box-binding protein, antihemoragic factor and natriuretic peptide. Some of them were not detected in earlier analyses of the venom of <italic toggle="yes">Vaa</italic> from Serbia, Croatia and Bulgaria [<xref rid="B47-vetsci-11-00605" ref-type="bibr">47</xref>,<xref rid="B49-vetsci-11-00605" ref-type="bibr">49</xref>,<xref rid="B50-vetsci-11-00605" ref-type="bibr">50</xref>].</p><p>Kunitz-type serine protease inhibitors (SPIs) have been identified in the venoms of Viperidae and Elapidae [<xref rid="B29-vetsci-11-00605" ref-type="bibr">29</xref>]. We detected four different Kunitz/BPTI peptides, one Kunitz/SPI and two MPI peptides. These peptides were not detected in the venom of the <italic toggle="yes">Vaa</italic> originating from Bulgaria [<xref rid="B49-vetsci-11-00605" ref-type="bibr">49</xref>].</p><p>PLA2, depending on the isoelectric point (pI), can be divided into acidic and basic isoforms, with the basic isoforms having a higher affinity for cell membranes and consequently a higher toxicity [<xref rid="B61-vetsci-11-00605" ref-type="bibr">61</xref>]. In our study, we have demonstrated the diversity of pI values of this enzyme by proteomic analysis. As a component of PLA2, amodytoxin A (AtxA) has the highest pI value compared to amoditoxin B and C and is also many times more toxic than the latter (<xref rid="vetsci-11-00605-t001" ref-type="table">Table 1</xref>). The overall abundance of PLA2 in the venom of the <italic toggle="yes">Vaa</italic> in our studies was lower compared to the venoms of the <italic toggle="yes">Vaa</italic> from Croatia and Bulgaria and amounted to 11.60%. Of these, 4.35% were neurotoxic amoditoxins (Atxs: A, B and C), while the remaining 7.25% were amoditins (Atns), which have no neurotoxic effect (<xref rid="vetsci-11-00605-t001" ref-type="table">Table 1</xref>). In this study, the relative abundance of amoditoxins and amoditins in the venom of <italic toggle="yes">Vaa</italic> is described in detail for the first time.</p><p>The most common neurotoxins are those that disrupt the somatic PNS by acting presynaptically (&#x003b2;-neurotoxins), postsynaptically (&#x003b1;-neurotoxins) or within the synaptic cleft [<xref rid="B62-vetsci-11-00605" ref-type="bibr">62</xref>,<xref rid="B63-vetsci-11-00605" ref-type="bibr">63</xref>]. In our working protocol, we used indirect and direct EFS to induce NPD contractions. Indirect EFS stimulates the presynaptic nerve terminal, resulting in the release of ACh, which activates the nicotinic acetylcholine receptor (nAChR) at the motor end-plate. This subsequently leads to the depolarization of the muscle cell and its contraction. Increasing concentrations of the competitive nAChR antagonist pancuronium (1 and 3 &#x003bc;M) reduce NPD contractions in a concentration-dependent manner, confirming with certainty that the parameters of indirect EFS are selective for the motor neuron. Direct EFS &#x0201c;bypasses&#x0201d; the neuromuscular synaptic cleft and triggers an NPD contraction through the direct activation of the contractile muscle machinery (actin&#x02013;myosin interaction). Under the influence of <italic toggle="yes">Vaa</italic> venom, there was a progressive decrease in NPD contractions (<xref rid="vetsci-11-00605-f005" ref-type="fig">Figure 5</xref>). The venom did not cause a change in the basal tension of the NPD. When we applied direct EFS parameters after an almost complete inhibition of indirect NPD contractions, the amplitude of NPD contractions reached values close to the control (<xref rid="vetsci-11-00605-f005" ref-type="fig">Figure 5</xref>). This finding indicates that <italic toggle="yes">Vaa</italic> venom at a concentration that has a significant neurotoxic effect does not exhibit myotoxicity in the diaphragm and does not cause disturbances at the level of the contractile muscle machinery. This result is consistent with Logonder et al. [<xref rid="B64-vetsci-11-00605" ref-type="bibr">64</xref>], who investigated the neurotoxicity of ammodytoxin A from <italic toggle="yes">Vaa</italic> using an isolated mouse diaphragm model.</p><p><xref rid="vetsci-11-00605-f006" ref-type="fig">Figure 6</xref> shows that the venom/antivenom mixture at the ratio of 1:2 reduces the neurotoxic effect of PLA2 but causes only a slight rightward shift of the time-dependent sigmoidal curve compared to the curve for the venom. The time-dependent sigmoidal curves for venom/antivenom mixtures at the ratios of 1:10 and 1:20 are clearly shifted to the right and have a lower slope than the curve for venom, especially the curve for the 1:20 mixture. In addition, there were highly significant (<italic toggle="yes">p</italic> &#x0003c; 0.001) differences between the ET<sub>50</sub> values for all three venom/antivenom ratios (<xref rid="vetsci-11-00605-f007" ref-type="fig">Figure 7</xref>). This proves that antivenom exerts a concentration-dependent protection of the decrease in NPD contractility as a function of time. Unfortunately, we were unable to compare this part of our results, as we found no studies in the literature that investigated the protective effect of the antivenom against the neurotoxic effects of the venom of <italic toggle="yes">Vaa</italic> using neuromuscular preparations of the diaphragm.</p><p>When examining NPD contractility, we noticed that the tetanic fade does not occur under the influence of <italic toggle="yes">Vaa</italic> venom (<xref rid="vetsci-11-00605-f008" ref-type="fig">Figure 8</xref>C, white arrows). Presynaptic &#x003b1;3&#x003b2;2 nicotinic autoreceptors facilitate the release of ACh (<xref rid="vetsci-11-00605-f008" ref-type="fig">Figure 8</xref>A, white arrows), ensuring reliable transmission at strategic sites such as neuromuscular synapses. <xref rid="vetsci-11-00605-f008" ref-type="fig">Figure 8</xref>B (black arrows) shows that the non-depolarizing neuromuscular blocker pancuronium leads to the appearance of a tetanic fade NPD, which is a consequence of the blockade of presynaptic &#x003b1;3&#x003b2;2 autoreceptors. However, there is evidence that the occurrence of tetanic fade cannot be explained simply and only by the blockade of the &#x003b1;3&#x003b2;2 autoreceptors. Other receptors, such as muscarinic and purinergic receptors, coexist with this receptor at presynaptic nerve terminals and also play an important role in modulating ACh release [<xref rid="B65-vetsci-11-00605" ref-type="bibr">65</xref>,<xref rid="B66-vetsci-11-00605" ref-type="bibr">66</xref>,<xref rid="B67-vetsci-11-00605" ref-type="bibr">67</xref>]. For example, studies have demonstrated that &#x003b1;-conotoxin MII, a highly selective antagonist of &#x003b1;3&#x003b2;2, does not induce tetanic fade, although it leads to reduced ACh release [<xref rid="B68-vetsci-11-00605" ref-type="bibr">68</xref>]. This implies high safety margins in neuromuscular transmission. For the above reasons, we can only conclude that PLA2 did not lead to tetanic fade under our experimental conditions and that further investigation is required for additional interpretation.</p><p>There are two ways in which AChE activity can be significantly altered, leading to the disruption of physiological neurotransmission. The first possibility is that the venom has high AChE activity (exogenous AChE), which leads to the increased hydrolysis of ACh in the synaptic cleft, resulting in the inhibition of neurotransmission [<xref rid="B13-vetsci-11-00605" ref-type="bibr">13</xref>]. High AChE activity was found in the venoms of snakes from the Elapidae family. In contrast, no AChE activity was found in snakes from the families Viperidae and Crotalidae [<xref rid="B69-vetsci-11-00605" ref-type="bibr">69</xref>]. The second possibility is that the venom inhibits AChE in the synaptic cleft. For example, this is characteristic of venoms from the Elapidae family, which contain the neurotoxin fasciculin (genus <italic toggle="yes">Dendroaspis</italic>&#x02014;mambas<italic toggle="yes">, D. angusticeps</italic>&#x02014;green mamba, <italic toggle="yes">D. polylepis</italic>&#x02014;black mamba, <italic toggle="yes">D. viridis</italic>&#x02014;western green mamba, <italic toggle="yes">D. jamesoni</italic>&#x02014;Jameson&#x02019;s mamba). The inhibition of AChE leads to fasciculations and spasms of the striated muscles [<xref rid="B9-vetsci-11-00605" ref-type="bibr">9</xref>]. Based on our results, no statistically significant difference was found in AChE activity in the diaphragm under the influence of the venom and the venom/antivenom mixtures in all mass ratios compared to the control group (<italic toggle="yes">p</italic> &#x0003e; 0.05) (<xref rid="vetsci-11-00605-f009" ref-type="fig">Figure 9</xref>). These results support the reports in the literature indicating that the enzyme AChE is not involved in the neurotoxic mechanism of action of the venom of Viperidae. This is also consistent with our proteomic analysis, which showed that AChE was not detected in <italic toggle="yes">Vaa</italic> venom.</p><p>The enzyme Na<sup>+</sup>/K<sup>+</sup>-ATPase (sodium-potassium pump) plays a decisive role in the generation of the concentration gradient across the cell membrane and the maintenance of the resting membrane potential. This enzyme consumes a considerable amount of energy for its function in many cells, especially in nerve and muscle cells. It is estimated that under standard resting conditions, 19 to 28% of total ATP in the body is used for Na<sup>+</sup>/K<sup>+</sup>-ATPase function. Under normal conditions, maintaining ionic gradients in brain neurons requires 50&#x02013;60% of total oxygen consumption coupled to ATP synthesis, most of which is consumed by the Na<sup>+</sup>/K<sup>+</sup>-pump [<xref rid="B70-vetsci-11-00605" ref-type="bibr">70</xref>,<xref rid="B71-vetsci-11-00605" ref-type="bibr">71</xref>,<xref rid="B72-vetsci-11-00605" ref-type="bibr">72</xref>,<xref rid="B73-vetsci-11-00605" ref-type="bibr">73</xref>]. These data indicate that the lack of the cellular energy currency ATP leads to a significant reduction in the activity of Na+/K+-ATPase, particularly in nervous tissue. Ammodytoxin A (AtxA), the most toxic PLA2 of the <italic toggle="yes">Vaa</italic> venom, is selectively and rapidly internalized into the presynaptic terminals of motor neurons and then translocated into the mitochondrial intermembrane space and matrix [<xref rid="B74-vetsci-11-00605" ref-type="bibr">74</xref>,<xref rid="B75-vetsci-11-00605" ref-type="bibr">75</xref>]. Moreover, Ivanu&#x00161;ec et al. [<xref rid="B74-vetsci-11-00605" ref-type="bibr">74</xref>] also found that the phospholipase activity of AtxA is not obligatory for its rapid intracellular and subcellular internalization. Since we have shown by the proteomic analysis of <italic toggle="yes">Vaa</italic> venom that AtxA is a protein with a low molecular weight of 15.5 kDa, we hypothesize that this could also be the reason for its rapid entry into mitochondrial structures. Mitochondria are very sensitive to fatty acids, lysophosphatides and PLA2, and their damage leads to a decrease in ATP production and the deenergization of terminal nerve endings [<xref rid="B64-vetsci-11-00605" ref-type="bibr">64</xref>]. As a result, the Na<sup>+</sup>/K<sup>+</sup>-ATPases lack energy support and their activity is inhibited. In this way, many important functions are disrupted, including the generation of axonal and synaptic membrane potentials and the mobilization of synaptic vesicles for the exocytosis of neurotransmitters [<xref rid="B76-vetsci-11-00605" ref-type="bibr">76</xref>]. In a study carried out on a neuromuscular preparation of the diaphragm, the neurotoxic effects of AtxA were investigated. Electron microscopy showed the most pronounced changes in the mitochondria of the presynaptic nerve endings. The mitochondria were swollen and damaged, with a disrupted mitochondrial cristae structure [<xref rid="B64-vetsci-11-00605" ref-type="bibr">64</xref>]. This finding supports our results showing that there is a highly significant (<italic toggle="yes">p</italic> &#x0003c; 0.001) inhibition of Na<sup>+</sup>/K<sup>+</sup>-ATPase in NPD under the influence of <italic toggle="yes">Vaa</italic> venom (<xref rid="vetsci-11-00605-f010" ref-type="fig">Figure 10</xref>). The mixture with the highest proportion of antivenom (1:20) almost completely restored Na<sup>+</sup>/K<sup>+</sup>-ATPase activity (94.55% of the control). The Pearson correlation revealed a very strong positive correlation (r = 0.9150, <italic toggle="yes">p</italic> &#x0003c; 0.001) between the increasing activity of the Na<sup>+</sup>/K<sup>+</sup>-ATPase and the increasing concentration of the antivenom. Therefore, we conclude that the antivenom effectively prevents the Vaa venom from causing a reduction in Na+/K+-ATPase activity. We did not find any studies on the effect of Viperidae venom on Na<sup>+</sup>/K<sup>+</sup>-ATPase activity in NPD in the available literature.</p><p>We investigated the activity of PLA2 in <italic toggle="yes">Vaa</italic> venom under in vitro conditions, both in the absence and presence of the antivenom. The results show that the antivenom completely neutralizes the activity of PLA2 at a mass ratio of venom/antivenom of 1:18 (<xref rid="vetsci-11-00605-f011" ref-type="fig">Figure 11</xref>B). We emphasize that this ratio corresponds approximately to the mass ratio of 1:20, which restores the activity of the Na<sup>+</sup>/K<sup>+</sup>-ATPase in the NPD to a level that is no longer statistically different from the control (Fugure 10). Due to the use of different methods to determine PLA2 enzyme activity, the use of different substrates and the expression of enzyme activity in different units, we were not able to compare the presented results with literature data.</p></sec><sec sec-type="conclusions" id="sec5-vetsci-11-00605"><title>5. Conclusions</title><p>With proteomic analysis, we have identified the complete composition of the <italic toggle="yes">Vaa</italic> venom, which gives us the opportunity to expand the database for <italic toggle="yes">Vaa</italic>. <italic toggle="yes">Vaa</italic> venom causes a progressive and significant decrease in the contractions of the NPD, without disturbance at the level of the contractile muscle machinery (actin&#x02013;myosin interaction) and without the occurrence of a tetanic fade. The antivenom abolished the venom-induced progressive decrease in NPD contractions in a concentration-dependent manner by inhibiting PLA2 activity. Under the influence of <italic toggle="yes">Vaa</italic> venom, there is no change in AChE activity in the NPD, indicating that the neurotoxic mechanism of action of <italic toggle="yes">Vaa</italic> venom is not mediated by this enzyme. <italic toggle="yes">Vaa</italic> venom leads to a pronounced inhibition of Na<sup>+</sup>/K<sup>+</sup>-ATPase activity in the NPD. Antivenom with approximately the same mass proportion almost completely restores Na<sup>+</sup>/K<sup>+</sup>-ATPase activity in the NPD and completely neutralizes the PLA2 activity of the venom in vitro. Considering the phospholipase activity of PLA2, our further studies will focus on investigating the parameters of oxidative stress in NPD under the influence of this component and the potential protective effect of the antivenom.</p></sec></body><back><ack><title>Acknowledgments</title><p>Special thanks to Vladimir Milovanovi&#x00107; for the original photo.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-11-00605"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vetsci11120605/s1">https://www.mdpi.com/article/10.3390/vetsci11120605/s1</uri>, Supplement S1 (Table S1: Master proteins fractions 0); Supplement S2 (Table S2: Venom Vaa identified proteins Serpentes DB; Table S3: Venom Vaa identified proteins Vipera DB; Table S4: Venom Vaa identified proteins Vipera ammodytes DB); Supplement S3 (Table S5: Protein groups fraction 0 all DB; Table S6: Serpentes DB protein groups; Table S7: Vipera DB protein groups; Table S8: Vipera ammodytes DB protein groups); Supplement S4 (Table S9: Protein groups all DB); Supplement S5 (Table S10: Bioinformatics for a Total of 159 identified proteins); Supplement S6 (Figure S1: Total ion chromatograms (TIC) for the complete venom, fraction 0 (panel A) and for DiffPOP protein fractions 3A (panel B), 5A (panel C), 8A (panel D), 9A (panel E) and 10A (panel F); Figure S2: Representative recording of contractions of a neuromuscular preparation of the diaphragm (NPD) induced by indirect EFS and direct EFS under the influence of a mixture of venom and antivenom in a ratio of 1:2 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>); Figure S3: Representative recording of contractions of a neuromuscular preparation of the diaphragm (NPD) induced by indirect EFS and direct EFS under the influence of a mixture of venom and antivenom at a ratio of 1:10 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>); Figure S4: Representative recording of contractions of a neuromuscular preparation of the diaphragm (NPD) induced by indirect EFS and direct EFS under the influence of a mixture of venom and antivenom at a ratio of 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>)).</p><supplementary-material id="vetsci-11-00605-s001" position="float" content-type="local-data"><media xlink:href="vetsci-11-00605-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, S.R.I., S.B. and I.&#x0017d;.; methodology, S.R.I., S.B., J.G.-M. and N.B.; software, I.R., D.R.M., V.M. and N.B.; validation, S.R.I., S.B. and D.R.M.; formal analysis, S.R.I., S.B., N.B. and D.R.M.; investigation, S.R.I., S.B. and I.&#x0017d;.; resources, I.&#x0017d;. and J.G.-M.; data curation, S.R.I., S.B. and D.R.M.; writing&#x02014;original draft preparation, S.R.I. and S.B.; writing&#x02014;review and editing, S.R.I., S.B., I.R., D.R.M. and V.M.; visualization, S.R.I., S.B. and D.R.M.; supervision, S.R.I. and S.B.; project administration, S.R.I. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Ethics Committee of the Institute of Virology, Vaccines and Sera &#x0201c;Torlak&#x0201d;, Republic of Serbia and the Veterinary Directorate of the Ministry of Agriculture of the Republic of Serbia (No. 323-07-02181/2021-05, 8 March 2021), which are in accordance with the EU Directive 2010/63/EU on the protection of animals used for scientific purposes.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article/<xref rid="app1-vetsci-11-00605" ref-type="app">Supplementary Materials</xref>; further inquiries can be directed to the corresponding author/s.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vetsci-11-00605"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minghui</surname><given-names>R.</given-names></name>
<name><surname>Malecela</surname><given-names>M.N.</given-names></name>
<name><surname>Cooke</surname><given-names>E.</given-names></name>
<name><surname>Abela-Ridder</surname><given-names>B.</given-names></name>
</person-group><article-title>WHO&#x02019;s Snakebite Envenoming Strategy for Prevention and Control</article-title><source>Lancet Glob. Health</source><year>2019</year><volume>7</volume><fpage>e837</fpage><lpage>e838</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(19)30225-6</pub-id><pub-id pub-id-type="pmid">31129124</pub-id>
</element-citation></ref><ref id="B2-vetsci-11-00605"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>R.A.</given-names></name>
<name><surname>Casewell</surname><given-names>N.R.</given-names></name>
<name><surname>Ainsworth</surname><given-names>S.A.</given-names></name>
<name><surname>Lalloo</surname><given-names>D.G.</given-names></name>
</person-group><article-title>The Time Is Now: A Call for Action to Translate Recent Momentum on Tackling Tropical Snakebite into Sustained Benefit for Victims</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>2019</year><volume>113</volume><fpage>835</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1093/trstmh/try134</pub-id><pub-id pub-id-type="pmid">30668842</pub-id>
</element-citation></ref><ref id="B3-vetsci-11-00605"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knudsen</surname><given-names>C.</given-names></name>
<name><surname>Ledsgaard</surname><given-names>L.</given-names></name>
<name><surname>Dehli</surname><given-names>R.I.</given-names></name>
<name><surname>Ahmadi</surname><given-names>S.</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>C.V.</given-names></name>
<name><surname>Laustsen</surname><given-names>A.H.</given-names></name>
</person-group><article-title>Engineering and Design Considerations for Next-Generation Snakebite Antivenoms</article-title><source>Toxicon Off. J. Int. Soc. Toxinol.</source><year>2019</year><volume>167</volume><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2019.06.005</pub-id><pub-id pub-id-type="pmid">31173790</pub-id>
</element-citation></ref><ref id="B4-vetsci-11-00605"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomovi&#x00107;</surname><given-names>L.</given-names></name>
<name><surname>An&#x00111;elkovi&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Krizmani&#x00107;</surname><given-names>I.</given-names></name>
<name><surname>Ajti&#x00107;</surname><given-names>R.</given-names></name>
<name><surname>Uro&#x00161;evi&#x00107;</surname><given-names>A.</given-names></name>
<name><surname>Labus</surname><given-names>N.</given-names></name>
<name><surname>Simovi&#x00107;</surname><given-names>A.</given-names></name>
<name><surname>Mari&#x0010d;i&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Golubovi&#x00107;</surname><given-names>A.</given-names></name>
<name><surname>&#x00106;orovi&#x00107;</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Distribution of Three Vipera Species in the Republic of Serbia</article-title><source>Bull. Nat. Hist. Mus.</source><year>2019</year><volume>12</volume><fpage>217</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.5937/bnhmb1912217T</pub-id></element-citation></ref><ref id="B5-vetsci-11-00605"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>Y.S.</given-names></name>
<name><surname>Cheung</surname><given-names>R.C.F.</given-names></name>
<name><surname>Xia</surname><given-names>L.</given-names></name>
<name><surname>Wong</surname><given-names>J.H.</given-names></name>
<name><surname>Ng</surname><given-names>T.B.</given-names></name>
<name><surname>Chan</surname><given-names>W.Y.</given-names></name>
</person-group><article-title>Snake Venom Toxins: Toxicity and Medicinal Applications</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2016</year><volume>100</volume><fpage>6165</fpage><lpage>6181</lpage><pub-id pub-id-type="doi">10.1007/s00253-016-7610-9</pub-id><pub-id pub-id-type="pmid">27245678</pub-id>
</element-citation></ref><ref id="B6-vetsci-11-00605"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munawar</surname><given-names>A.</given-names></name>
<name><surname>Ali</surname><given-names>S.A.</given-names></name>
<name><surname>Akrem</surname><given-names>A.</given-names></name>
<name><surname>Betzel</surname><given-names>C.</given-names></name>
</person-group><article-title>Snake Venom Peptides: Tools of Biodiscovery</article-title><source>Toxins</source><year>2018</year><volume>10</volume><elocation-id>474</elocation-id><pub-id pub-id-type="doi">10.3390/toxins10110474</pub-id><pub-id pub-id-type="pmid">30441876</pub-id>
</element-citation></ref><ref id="B7-vetsci-11-00605"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pandit</surname><given-names>K.</given-names></name>
<name><surname>Rawal</surname><given-names>A.</given-names></name>
<name><surname>Maskey</surname><given-names>H.M.S.</given-names></name>
<name><surname>Nepal</surname><given-names>G.</given-names></name>
</person-group><article-title>Neurological and Neuro-Ophthalmological Manifestations of Snake Bite: A Systematic Review</article-title><source>Ann. Med. Surg.</source><year>2024</year><volume>86</volume><fpage>392</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1097/MS9.0000000000001523</pub-id></element-citation></ref><ref id="B8-vetsci-11-00605"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>A.</given-names></name>
<name><surname>Hodgson</surname><given-names>W.C.</given-names></name>
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
</person-group><article-title>Antivenom for Neuromuscular Paralysis Resulting From Snake Envenoming</article-title><source>Toxins</source><year>2017</year><volume>9</volume><elocation-id>143</elocation-id><pub-id pub-id-type="doi">10.3390/toxins9040143</pub-id><pub-id pub-id-type="pmid">28422078</pub-id>
</element-citation></ref><ref id="B9-vetsci-11-00605"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ranawaka</surname><given-names>U.K.</given-names></name>
<name><surname>Lalloo</surname><given-names>D.G.</given-names></name>
<name><surname>de Silva</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Neurotoxicity in Snakebite--the Limits of Our Knowledge</article-title><source>PLoS Negl. Trop. Dis.</source><year>2013</year><volume>7</volume><elocation-id>e2302</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002302</pub-id><pub-id pub-id-type="pmid">24130909</pub-id>
</element-citation></ref><ref id="B10-vetsci-11-00605"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>A.</given-names></name>
<name><surname>Maduwage</surname><given-names>K.</given-names></name>
<name><surname>Sedgwick</surname><given-names>M.</given-names></name>
<name><surname>Pilapitiya</surname><given-names>S.</given-names></name>
<name><surname>Weerawansa</surname><given-names>P.</given-names></name>
<name><surname>Dahanayaka</surname><given-names>N.J.</given-names></name>
<name><surname>Buckley</surname><given-names>N.A.</given-names></name>
<name><surname>Johnston</surname><given-names>C.</given-names></name>
<name><surname>Siribaddana</surname><given-names>S.</given-names></name>
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
</person-group><article-title>Neuromuscular Effects of Common Krait (Bungarus Caeruleus) Envenoming in Sri Lanka</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004368</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004368</pub-id><pub-id pub-id-type="pmid">26829229</pub-id>
</element-citation></ref><ref id="B11-vetsci-11-00605"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>A.</given-names></name>
<name><surname>Maduwage</surname><given-names>K.</given-names></name>
<name><surname>Sedgwick</surname><given-names>M.</given-names></name>
<name><surname>Pilapitiya</surname><given-names>S.</given-names></name>
<name><surname>Weerawansa</surname><given-names>P.</given-names></name>
<name><surname>Dahanayaka</surname><given-names>N.J.</given-names></name>
<name><surname>Buckley</surname><given-names>N.A.</given-names></name>
<name><surname>Siribaddana</surname><given-names>S.</given-names></name>
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
</person-group><article-title>Neurotoxicity in Russell&#x02019;s Viper (Daboia Russelii) Envenoming in Sri Lanka: A Clinical and Neurophysiological Study</article-title><source>Clin. Toxicol.</source><year>2016</year><volume>54</volume><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.3109/15563650.2016.1143556</pub-id><pub-id pub-id-type="pmid">26923566</pub-id>
</element-citation></ref><ref id="B12-vetsci-11-00605"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hodgson</surname><given-names>W.C.</given-names></name>
<name><surname>Wickramaratna</surname><given-names>J.C.</given-names></name>
</person-group><article-title><italic toggle="yes">In Vitro</italic> Neuromuscular Activity of Snake Venoms</article-title><source>Clin. Exp. Pharmacol. Physiol.</source><year>2002</year><volume>29</volume><fpage>807</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1681.2002.03740.x</pub-id><pub-id pub-id-type="pmid">12165047</pub-id>
</element-citation></ref><ref id="B13-vetsci-11-00605"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bickler</surname><given-names>P.E.</given-names></name>
<name><surname>Abouyannis</surname><given-names>M.</given-names></name>
<name><surname>Bhalla</surname><given-names>A.</given-names></name>
<name><surname>Lewin</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Neuromuscular Weakness and Paralysis Produced by Snakebite Envenoming: Mechanisms and Proposed Standards for Clinical Assessment</article-title><source>Toxins</source><year>2023</year><volume>15</volume><elocation-id>49</elocation-id><pub-id pub-id-type="doi">10.3390/toxins15010049</pub-id><pub-id pub-id-type="pmid">36668869</pub-id>
</element-citation></ref><ref id="B14-vetsci-11-00605"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>A.L.</given-names></name>
<name><surname>Viegas</surname><given-names>M.F.</given-names></name>
<name><surname>Da Silva</surname><given-names>S.L.</given-names></name>
<name><surname>Soares</surname><given-names>A.M.</given-names></name>
<name><surname>Ramos</surname><given-names>M.J.</given-names></name>
<name><surname>Fernandes</surname><given-names>P.A.</given-names></name>
</person-group><article-title>The Chemistry of Snake Venom and Its Medicinal Potential</article-title><source>Nat. Rev. Chem.</source><year>2022</year><volume>6</volume><fpage>451</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41570-022-00393-7</pub-id></element-citation></ref><ref id="B15-vetsci-11-00605"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castro-Amorim</surname><given-names>J.</given-names></name>
<name><surname>Novo de Oliveira</surname><given-names>A.</given-names></name>
<name><surname>Da Silva</surname><given-names>S.L.</given-names></name>
<name><surname>Soares</surname><given-names>A.M.</given-names></name>
<name><surname>Mukherjee</surname><given-names>A.K.</given-names></name>
<name><surname>Ramos</surname><given-names>M.J.</given-names></name>
<name><surname>Fernandes</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Na/K-ATPase_Catalytically Active Snake Venom PLA2 Enzymes: An Overview of Its Elusive Mechanisms of Reaction</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>5364</fpage><lpage>5376</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00097</pub-id><pub-id pub-id-type="pmid">37018514</pub-id>
</element-citation></ref><ref id="B16-vetsci-11-00605"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bittenbinder</surname><given-names>M.A.</given-names></name>
<name><surname>van Thiel</surname><given-names>J.</given-names></name>
<name><surname>Cardoso</surname><given-names>F.C.</given-names></name>
<name><surname>Casewell</surname><given-names>N.R.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.-M.</given-names></name>
<name><surname>Kool</surname><given-names>J.</given-names></name>
<name><surname>Vonk</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Tissue Damaging Toxins in Snake Venoms: Mechanisms of Action, Pathophysiology and Treatment Strategies</article-title><source>Commun. Biol.</source><year>2024</year><volume>7</volume><elocation-id>358</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-024-06019-6</pub-id><pub-id pub-id-type="pmid">38519650</pub-id>
</element-citation></ref><ref id="B17-vetsci-11-00605"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tonello</surname><given-names>F.</given-names></name>
<name><surname>Simonato</surname><given-names>M.</given-names></name>
<name><surname>Aita</surname><given-names>A.</given-names></name>
<name><surname>Pizzo</surname><given-names>P.</given-names></name>
<name><surname>Fern&#x000e1;ndez</surname><given-names>J.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Montecucco</surname><given-names>C.</given-names></name>
</person-group><article-title>A Lys49-PLA2 Myotoxin of Bothrops Asper Triggers a Rapid Death of Macrophages That Involves Autocrine Purinergic Receptor Signaling</article-title><source>Cell Death Dis.</source><year>2012</year><volume>3</volume><fpage>e343</fpage><pub-id pub-id-type="doi">10.1038/cddis.2012.68</pub-id><pub-id pub-id-type="pmid">22764102</pub-id>
</element-citation></ref><ref id="B18-vetsci-11-00605"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x00160;ribar</surname><given-names>J.</given-names></name>
<name><surname>Ober&#x0010d;kal</surname><given-names>J.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
</person-group><article-title>Understanding the Molecular Mechanism Underlying the Presynaptic Toxicity of Secreted Phospholipases A2: An Update</article-title><source>Toxicon</source><year>2014</year><volume>89</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2014.06.019</pub-id><pub-id pub-id-type="pmid">25009088</pub-id>
</element-citation></ref><ref id="B19-vetsci-11-00605"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirakosyan</surname><given-names>G.</given-names></name>
<name><surname>Mohamadvarzi</surname><given-names>M.</given-names></name>
<name><surname>Ghulikyan</surname><given-names>L.</given-names></name>
<name><surname>Zaqaryan</surname><given-names>N.</given-names></name>
<name><surname>Kishmiryan</surname><given-names>A.</given-names></name>
<name><surname>Ayvazyan</surname><given-names>N.</given-names></name>
</person-group><article-title>Morphological and Functional Alteration of Erythrocyte Ghosts and Giant Unilamellar Vesicles Caused by Vipera Latifi Venom</article-title><source>Comp. Biochem. Physiol. Part C Toxicol. Pharmacol.</source><year>2016</year><volume>190</volume><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.cbpc.2016.08.006</pub-id></element-citation></ref><ref id="B20-vetsci-11-00605"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jayaraman</surname><given-names>G.</given-names></name>
<name><surname>Krishnaswamy</surname><given-names>T.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
</person-group><article-title>Binding of Nucleotide Triphosphates to Cardiotoxin Analogue II from the Taiwan Cobra Venom (Naja Naja Atra). Elucidation of the Structural Interactions in the dATP-Cardiotoxin Analogue Ii Complex</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>17869</fpage><lpage>17875</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.25.17869</pub-id><pub-id pub-id-type="pmid">10364232</pub-id>
</element-citation></ref><ref id="B21-vetsci-11-00605"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>T.K.S.</given-names></name>
<name><surname>Jayaraman</surname><given-names>G.</given-names></name>
<name><surname>Lee</surname><given-names>C.S.</given-names></name>
<name><surname>Arunkumar</surname><given-names>A.I.</given-names></name>
<name><surname>Sivaraman</surname><given-names>T.</given-names></name>
<name><surname>Samuel</surname><given-names>D.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
</person-group><article-title>Snake Venom Cardiotoxins-Structure, Dynamics, Function and Folding</article-title><source>J. Biomol. Struct. Dyn.</source><year>1997</year><volume>15</volume><fpage>431</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1080/07391102.1997.10508957</pub-id><pub-id pub-id-type="pmid">9439993</pub-id>
</element-citation></ref><ref id="B22-vetsci-11-00605"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bougis</surname><given-names>P.E.</given-names></name>
<name><surname>KhElif</surname><given-names>A.</given-names></name>
<name><surname>Rochat</surname><given-names>H.</given-names></name>
</person-group><article-title>On the Inhibition of [Na+,K+]-ATPasesby the Components of Naja Mossambica Activities Mossambica Venom: Evidence for Two Distinct Rat Brain [Na+,K+]-ATPase</article-title><source>Biochemistry</source><year>1989</year><volume>28</volume><fpage>3037</fpage><lpage>3043</lpage><pub-id pub-id-type="doi">10.1021/bi00433a045</pub-id><pub-id pub-id-type="pmid">2545244</pub-id>
</element-citation></ref><ref id="B23-vetsci-11-00605"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaplia</surname><given-names>A.A.</given-names></name>
<name><surname>Kravtsova</surname><given-names>V.V.</given-names></name>
<name><surname>Kravtsov</surname><given-names>A.V.</given-names></name>
</person-group><article-title>[Effect of phospholipase A2 from Naja naja oxiana venom on activity of Na+,K+-ATPase isoenzymes in rat brain]</article-title><source>Biokhimiia Mosc. Russ.</source><year>1996</year><volume>61</volume><fpage>998</fpage><lpage>1005</lpage></element-citation></ref><ref id="B24-vetsci-11-00605"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leite</surname><given-names>R.S.</given-names></name>
<name><surname>Pinheiro</surname><given-names>G.H.D.</given-names></name>
<name><surname>Fernandes</surname><given-names>M.N.</given-names></name>
<name><surname>Selistre-de-Araujo</surname><given-names>H.S.</given-names></name>
</person-group><article-title>The Effect of the Myotoxic Lys49 Phospholipase A(2) from Agkistrodon Contortrix Laticinctus Snake Venom on Na+/K+ -ATPase Activity of Toad Bladders</article-title><source>Toxicol. Vitro Int. J. Publ. Assoc. BIBRA</source><year>2006</year><volume>20</volume><fpage>1478</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2006.05.004</pub-id></element-citation></ref><ref id="B25-vetsci-11-00605"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leite</surname><given-names>R.S.</given-names></name>
<name><surname>Franco</surname><given-names>W.</given-names></name>
<name><surname>Ownby</surname><given-names>C.L.</given-names></name>
<name><surname>Selistre-de-Araujo</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Effects of ACL Myotoxin, a Lys49 Phospholipase A(2) from Agkistrodon Contortrix Laticinctus Snake Venom, on Water Transport in the Isolated Toad Urinary Bladder</article-title><source>Toxicon Off. J. Int. Soc. Toxinol.</source><year>2004</year><volume>43</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2003.10.024</pub-id></element-citation></ref><ref id="B26-vetsci-11-00605"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamb</surname><given-names>T.</given-names></name>
<name><surname>De Haro</surname><given-names>L.</given-names></name>
<name><surname>Lonati</surname><given-names>D.</given-names></name>
<name><surname>Brvar</surname><given-names>M.</given-names></name>
<name><surname>Eddleston</surname><given-names>M.</given-names></name>
</person-group><article-title>Antivenom for European <italic toggle="yes">Vipera</italic> Species Envenoming</article-title><source>Clin. Toxicol.</source><year>2017</year><volume>55</volume><fpage>557</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1080/15563650.2017.1300261</pub-id></element-citation></ref><ref id="B27-vetsci-11-00605"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobaja Borak</surname><given-names>M.</given-names></name>
<name><surname>Babi&#x00107;</surname><given-names>&#x0017d;.</given-names></name>
<name><surname>Caganova</surname><given-names>B.</given-names></name>
<name><surname>Grenc</surname><given-names>D.</given-names></name>
<name><surname>Karabuva</surname><given-names>S.</given-names></name>
<name><surname>Kolpach</surname><given-names>Z.</given-names></name>
<name><surname>Krakowiak</surname><given-names>A.</given-names></name>
<name><surname>Kolesnikova</surname><given-names>V.</given-names></name>
<name><surname>Luk&#x00161;i&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>Pap</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Viper Envenomation in Central and Southeastern Europe: A Multicentre Study</article-title><source>Clin. Toxicol.</source><year>2023</year><volume>61</volume><fpage>656</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1080/15563650.2023.2273761</pub-id></element-citation></ref><ref id="B28-vetsci-11-00605"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Latinovi&#x00107;</surname><given-names>Z.</given-names></name>
<name><surname>Leonardi</surname><given-names>A.</given-names></name>
<name><surname>&#x00160;ribar</surname><given-names>J.</given-names></name>
<name><surname>Sajevic</surname><given-names>T.</given-names></name>
<name><surname>&#x0017d;u&#x0017e;ek</surname><given-names>M.C.</given-names></name>
<name><surname>Frange&#x0017e;</surname><given-names>R.</given-names></name>
<name><surname>Halassy</surname><given-names>B.</given-names></name>
<name><surname>Trampu&#x00161;-Bakija</surname><given-names>A.</given-names></name>
<name><surname>Punger&#x0010d;ar</surname><given-names>J.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
</person-group><article-title>Venomics of Vipera Berus Berus to Explain Differences in Pathology Elicited by Vipera Ammodytes Ammodytes Envenomation: Therapeutic Implications</article-title><source>J. Proteom.</source><year>2016</year><volume>146</volume><fpage>34</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2016.06.020</pub-id></element-citation></ref><ref id="B29-vetsci-11-00605"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giribaldi</surname><given-names>J.</given-names></name>
<name><surname>Kazandjian</surname><given-names>T.</given-names></name>
<name><surname>Amorim</surname><given-names>F.G.</given-names></name>
<name><surname>Whiteley</surname><given-names>G.</given-names></name>
<name><surname>Wagstaff</surname><given-names>S.C.</given-names></name>
<name><surname>Cazals</surname><given-names>G.</given-names></name>
<name><surname>Enjalbal</surname><given-names>C.</given-names></name>
<name><surname>Quinton</surname><given-names>L.</given-names></name>
<name><surname>Casewell</surname><given-names>N.R.</given-names></name>
<name><surname>Dutertre</surname><given-names>S.</given-names></name>
</person-group><article-title>Venomics of the Asp Viper Vipera Aspis Aspis from France</article-title><source>J. Proteom.</source><year>2020</year><volume>218</volume><fpage>103707</fpage><pub-id pub-id-type="doi">10.1016/j.jprot.2020.103707</pub-id></element-citation></ref><ref id="B30-vetsci-11-00605"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgieva</surname><given-names>D.</given-names></name>
<name><surname>Arni</surname><given-names>R.K.</given-names></name>
<name><surname>Betzel</surname><given-names>C.</given-names></name>
</person-group><article-title>Proteome Analysis of Snake Venom Toxins: Pharmacological Insights</article-title><source>Expert Rev. Proteom.</source><year>2008</year><volume>5</volume><fpage>787</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1586/14789450.5.6.787</pub-id></element-citation></ref><ref id="B31-vetsci-11-00605"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tasoulis</surname><given-names>T.</given-names></name>
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
</person-group><article-title>A Current Perspective on Snake Venom Composition and Constituent Protein Families</article-title><source>Arch. Toxicol.</source><year>2023</year><volume>97</volume><fpage>133</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1007/s00204-022-03420-0</pub-id><pub-id pub-id-type="pmid">36437303</pub-id>
</element-citation></ref><ref id="B32-vetsci-11-00605"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lukic</surname><given-names>I.</given-names></name>
<name><surname>Blagojevic</surname><given-names>V.</given-names></name>
<name><surname>Minic</surname><given-names>R.</given-names></name>
<name><surname>Ivanovic</surname><given-names>S.</given-names></name>
<name><surname>Borozan</surname><given-names>S.</given-names></name>
<name><surname>Cupic</surname><given-names>V.</given-names></name>
<name><surname>Zivkovic</surname><given-names>I.</given-names></name>
</person-group><article-title>Comparison of Cytotoxicity Methods for Studying Vipera Ammodytes Venom and the Anticytotoxic Potency of Antivenom</article-title><source>Cent.-Eur. J. Immunol.</source><year>2024</year><volume>49</volume><fpage>94</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.5114/ceji.2024.142417</pub-id><pub-id pub-id-type="pmid">39381561</pub-id>
</element-citation></ref><ref id="B33-vetsci-11-00605"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinto</surname><given-names>A.F.M.</given-names></name>
<name><surname>Diedrich</surname><given-names>J.K.</given-names></name>
<name><surname>Moresco</surname><given-names>J.J.</given-names></name>
<name><surname>Yates</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Differential Precipitation of Proteins: A Simple Protein Fractionation Strategy to Gain Biological Insights with Proteomics</article-title><source>J. Am. Soc. Mass Spectrom.</source><year>2023</year><volume>34</volume><fpage>2025</fpage><lpage>2033</lpage><pub-id pub-id-type="doi">10.1021/jasms.3c00182</pub-id><pub-id pub-id-type="pmid">37527410</pub-id>
</element-citation></ref><ref id="B34-vetsci-11-00605"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Re&#x00161;etar Maslov</surname><given-names>D.</given-names></name>
<name><surname>Rubi&#x00107;</surname><given-names>I.</given-names></name>
<name><surname>Farka&#x00161;</surname><given-names>V.</given-names></name>
<name><surname>Kule&#x00161;</surname><given-names>J.</given-names></name>
<name><surname>Beer Ljubi&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>Beleti&#x00107;</surname><given-names>A.</given-names></name>
<name><surname>Samard&#x0017e;ija</surname><given-names>M.</given-names></name>
<name><surname>Kova&#x0010d;i&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Jurki&#x00107; Krsteska</surname><given-names>G.</given-names></name>
<name><surname>Mrljak</surname><given-names>V.</given-names></name>
</person-group><article-title>Characterization and LC-MS/MS Based Proteomic Analysis of Extracellular Vesicles Separated from Blood Serum of Healthy and Dogs Naturally Infected by Babesia Canis. A Preliminary Study</article-title><source>Vet. Parasitol.</source><year>2024</year><volume>328</volume><fpage>110188</fpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2024.110188</pub-id><pub-id pub-id-type="pmid">38653059</pub-id>
</element-citation></ref><ref id="B35-vetsci-11-00605"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Re&#x00161;etar Maslov</surname><given-names>D.</given-names></name>
<name><surname>Farka&#x00161;</surname><given-names>V.</given-names></name>
<name><surname>Rubi&#x00107;</surname><given-names>I.</given-names></name>
<name><surname>Kule&#x00161;</surname><given-names>J.</given-names></name>
<name><surname>Beleti&#x00107;</surname><given-names>A.</given-names></name>
<name><surname>Beer Ljubi&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>&#x00160;mit</surname><given-names>I.</given-names></name>
<name><surname>Mrljak</surname><given-names>V.</given-names></name>
<name><surname>Torti</surname><given-names>M.</given-names></name>
</person-group><article-title>Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>7142</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24087142</pub-id><pub-id pub-id-type="pmid">37108311</pub-id>
</element-citation></ref><ref id="B36-vetsci-11-00605"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Solano</surname><given-names>G.</given-names></name>
<name><surname>Pla</surname><given-names>D.</given-names></name>
<name><surname>Herrera</surname><given-names>M.</given-names></name>
<name><surname>Segura</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>Vargas</surname><given-names>M.</given-names></name>
<name><surname>Villalta</surname><given-names>M.</given-names></name>
<name><surname>S&#x000e1;nchez</surname><given-names>A.</given-names></name>
<name><surname>Sanz</surname><given-names>L.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Preclinical Evaluation of the Efficacy of Antivenoms for Snakebite Envenoming: State-of-the-Art and Challenges Ahead</article-title><source>Toxins</source><year>2017</year><volume>9</volume><elocation-id>163</elocation-id><pub-id pub-id-type="doi">10.3390/toxins9050163</pub-id><pub-id pub-id-type="pmid">28505100</pub-id>
</element-citation></ref><ref id="B37-vetsci-11-00605"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krummer</surname><given-names>S.</given-names></name>
<name><surname>Thiermann</surname><given-names>H.</given-names></name>
<name><surname>Worek</surname><given-names>F.</given-names></name>
<name><surname>Eyer</surname><given-names>P.</given-names></name>
</person-group><article-title>Equipotent Cholinesterase Reactivation in Vitro by the Nerve Agent Antidotes HI 6 Dichloride and HI 6 Dimethanesulfonate</article-title><source>Arch. Toxicol.</source><year>2002</year><volume>76</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1007/s00204-002-0382-2</pub-id><pub-id pub-id-type="pmid">12373455</pub-id>
</element-citation></ref><ref id="B38-vetsci-11-00605"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellman</surname><given-names>G.L.</given-names></name>
<name><surname>Courtney</surname><given-names>K.D.</given-names></name>
<name><surname>Andres</surname><given-names>V.</given-names></name>
<name><surname>Feather-Stone</surname><given-names>R.M.</given-names></name>
</person-group><article-title>A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity</article-title><source>Biochem. Pharmacol.</source><year>1961</year><volume>7</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(61)90145-9</pub-id><pub-id pub-id-type="pmid">13726518</pub-id>
</element-citation></ref><ref id="B39-vetsci-11-00605"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lowry</surname><given-names>O.H.</given-names></name>
<name><surname>Rosebrough</surname><given-names>N.J.</given-names></name>
<name><surname>Farr</surname><given-names>A.L.</given-names></name>
<name><surname>Randall</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Protein Measurement with the Folin Phenol Reagent</article-title><source>J. Biol. Chem.</source><year>1951</year><volume>193</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(19)52451-6</pub-id><pub-id pub-id-type="pmid">14907713</pub-id>
</element-citation></ref><ref id="B40-vetsci-11-00605"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pari</surname><given-names>L.</given-names></name>
<name><surname>Murugavel</surname><given-names>P.</given-names></name>
</person-group><article-title>Diallyl Tetrasulfide Improves Cadmium Induced Alterations of Acetylcholinesterase, ATPases and Oxidative Stress in Brain of Rats</article-title><source>Toxicology</source><year>2007</year><volume>234</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2007.01.021</pub-id><pub-id pub-id-type="pmid">17337106</pub-id>
</element-citation></ref><ref id="B41-vetsci-11-00605"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>N.H.</given-names></name>
<name><surname>Tan</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Acidimetric Assay for Phospholipase A Using Egg Yolk Suspension as Substrate</article-title><source>Anal. Biochem.</source><year>1988</year><volume>170</volume><fpage>282</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(88)90632-X</pub-id><pub-id pub-id-type="pmid">3394929</pub-id>
</element-citation></ref><ref id="B42-vetsci-11-00605"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prijatelj</surname><given-names>P.</given-names></name>
<name><surname>Copic</surname><given-names>A.</given-names></name>
<name><surname>Krizaj</surname><given-names>I.</given-names></name>
<name><surname>Gubensek</surname><given-names>F.</given-names></name>
<name><surname>Pungercar</surname><given-names>J.</given-names></name>
</person-group><article-title>Charge Reversal of Ammodytoxin A, a Phospholipase A2-Toxin, Does Not Abolish Its Neurotoxicity</article-title><source>Biochem. J.</source><year>2000</year><volume>352</volume><issue-part>Pt 2</issue-part><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1042/bj3520251</pub-id><pub-id pub-id-type="pmid">11085916</pub-id>
</element-citation></ref><ref id="B43-vetsci-11-00605"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kerkkamp</surname><given-names>H.M.I.</given-names></name>
<name><surname>Kini</surname><given-names>R.M.</given-names></name>
<name><surname>Pospelov</surname><given-names>A.S.</given-names></name>
<name><surname>Vonk</surname><given-names>F.J.</given-names></name>
<name><surname>Henkel</surname><given-names>C.V.</given-names></name>
<name><surname>Richardson</surname><given-names>M.K.</given-names></name>
</person-group><article-title>Snake Genome Sequencing: Results and Future Prospects</article-title><source>Toxins</source><year>2016</year><volume>8</volume><elocation-id>360</elocation-id><pub-id pub-id-type="doi">10.3390/toxins8120360</pub-id><pub-id pub-id-type="pmid">27916957</pub-id>
</element-citation></ref><ref id="B44-vetsci-11-00605"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Modahl</surname><given-names>C.M.</given-names></name>
<name><surname>Brahma</surname><given-names>R.K.</given-names></name>
<name><surname>Koh</surname><given-names>C.Y.</given-names></name>
<name><surname>Shioi</surname><given-names>N.</given-names></name>
<name><surname>Kini</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Omics Technologies for Profiling Toxin Diversity and Evolution in Snake Venom: Impacts on the Discovery of Therapeutic and Diagnostic Agents</article-title><source>Annu. Rev. Anim. Biosci.</source><year>2020</year><volume>8</volume><fpage>91</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1146/annurev-animal-021419-083626</pub-id><pub-id pub-id-type="pmid">31702940</pub-id>
</element-citation></ref><ref id="B45-vetsci-11-00605"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damm</surname><given-names>M.</given-names></name>
<name><surname>Hempel</surname><given-names>B.-F.</given-names></name>
<name><surname>S&#x000fc;ssmuth</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Old World Vipers-A Review about Snake Venom Proteomics of Viperinae and Their Variations</article-title><source>Toxins</source><year>2021</year><volume>13</volume><elocation-id>427</elocation-id><pub-id pub-id-type="doi">10.3390/toxins13060427</pub-id><pub-id pub-id-type="pmid">34204565</pub-id>
</element-citation></ref><ref id="B46-vetsci-11-00605"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petras</surname><given-names>D.</given-names></name>
<name><surname>Hempel</surname><given-names>B.-F.</given-names></name>
<name><surname>G&#x000f6;&#x000e7;men</surname><given-names>B.</given-names></name>
<name><surname>Karis</surname><given-names>M.</given-names></name>
<name><surname>Whiteley</surname><given-names>G.</given-names></name>
<name><surname>Wagstaff</surname><given-names>S.C.</given-names></name>
<name><surname>Heiss</surname><given-names>P.</given-names></name>
<name><surname>Casewell</surname><given-names>N.R.</given-names></name>
<name><surname>Nalbantsoy</surname><given-names>A.</given-names></name>
<name><surname>S&#x000fc;ssmuth</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Intact Protein Mass Spectrometry Reveals Intraspecies Variations in Venom Composition of a Local Population of Vipera Kaznakovi in Northeastern Turkey</article-title><source>J. Proteom.</source><year>2019</year><volume>199</volume><fpage>31</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2019.02.004</pub-id></element-citation></ref><ref id="B47-vetsci-11-00605"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gopcevic</surname><given-names>K.</given-names></name>
<name><surname>Karadzic</surname><given-names>I.</given-names></name>
<name><surname>Izrael-Zivkovic</surname><given-names>L.</given-names></name>
<name><surname>Medic</surname><given-names>A.</given-names></name>
<name><surname>Isakovic</surname><given-names>A.</given-names></name>
<name><surname>Popovi&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Kekic</surname><given-names>D.</given-names></name>
<name><surname>Stanojkovic</surname><given-names>T.</given-names></name>
<name><surname>Hozic</surname><given-names>A.</given-names></name>
<name><surname>Cindric</surname><given-names>M.</given-names></name>
</person-group><article-title>Study of the Venom Proteome of Vipera Ammodytes Ammodytes (Linnaeus, 1758): A Qualitative Overview, Biochemical and Biological Profiling</article-title><source>Comp. Biochem. Physiol. Part D Genom. Proteom.</source><year>2021</year><volume>37</volume><elocation-id>100776</elocation-id><pub-id pub-id-type="doi">10.1016/j.cbd.2020.100776</pub-id></element-citation></ref><ref id="B48-vetsci-11-00605"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Casewell</surname><given-names>N.R.</given-names></name>
<name><surname>Jackson</surname><given-names>T.N.W.</given-names></name>
<name><surname>Laustsen</surname><given-names>A.H.</given-names></name>
<name><surname>Sunagar</surname><given-names>K.</given-names></name>
</person-group><article-title>Causes and Consequences of Snake Venom Variation</article-title><source>Trends Pharmacol. Sci.</source><year>2020</year><volume>41</volume><fpage>570</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2020.05.006</pub-id><pub-id pub-id-type="pmid">32564899</pub-id>
</element-citation></ref><ref id="B49-vetsci-11-00605"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgieva</surname><given-names>D.</given-names></name>
<name><surname>Risch</surname><given-names>M.</given-names></name>
<name><surname>Kardas</surname><given-names>A.</given-names></name>
<name><surname>Buck</surname><given-names>F.</given-names></name>
<name><surname>von Bergen</surname><given-names>M.</given-names></name>
<name><surname>Betzel</surname><given-names>C.</given-names></name>
</person-group><article-title>Comparative Analysis of the Venom Proteomes of Vipera Ammodytes Ammodytes and Vipera Ammodytes Meridionalis</article-title><source>J. Proteome Res.</source><year>2008</year><volume>7</volume><fpage>866</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1021/pr070376c</pub-id><pub-id pub-id-type="pmid">18257516</pub-id>
</element-citation></ref><ref id="B50-vetsci-11-00605"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leonardi</surname><given-names>A.</given-names></name>
<name><surname>Sajevic</surname><given-names>T.</given-names></name>
<name><surname>Punger&#x0010d;ar</surname><given-names>J.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
</person-group><article-title>Comprehensive Study of the Proteome and Transcriptome of the Venom of the Most Venomous European Viper: Discovery of a New Subclass of Ancestral Snake Venom Metalloproteinase Precursor-Derived Proteins</article-title><source>J. Proteome Res.</source><year>2019</year><volume>18</volume><fpage>2287</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.9b00120</pub-id><pub-id pub-id-type="pmid">31017792</pub-id>
</element-citation></ref><ref id="B51-vetsci-11-00605"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sajevic</surname><given-names>T.</given-names></name>
<name><surname>Leonardi</surname><given-names>A.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
</person-group><article-title>An Overview of Hemostatically Active Components of <italic toggle="yes">Vipera Ammodytes Ammodytes</italic> Venom</article-title><source>Toxin Rev.</source><year>2014</year><volume>33</volume><fpage>33</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.3109/15569543.2013.835827</pub-id></element-citation></ref><ref id="B52-vetsci-11-00605"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanchez</surname><given-names>E.F.</given-names></name>
<name><surname>Flores-Ortiz</surname><given-names>R.J.</given-names></name>
<name><surname>Alvarenga</surname><given-names>V.G.</given-names></name>
<name><surname>Eble</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Direct Fibrinolytic Snake Venom Metalloproteinases Affecting Hemostasis: Structural, Biochemical Features and Therapeutic Potential</article-title><source>Toxins</source><year>2017</year><volume>9</volume><elocation-id>392</elocation-id><pub-id pub-id-type="doi">10.3390/toxins9120392</pub-id><pub-id pub-id-type="pmid">29206190</pub-id>
</element-citation></ref><ref id="B53-vetsci-11-00605"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Escalante</surname><given-names>T.</given-names></name>
<name><surname>Rucavado</surname><given-names>A.</given-names></name>
<name><surname>Herrera</surname><given-names>C.</given-names></name>
</person-group><article-title>Hemorrhage Caused by Snake Venom Metalloproteinases: A Journey of Discovery and Understanding</article-title><source>Toxins</source><year>2016</year><volume>8</volume><elocation-id>93</elocation-id><pub-id pub-id-type="doi">10.3390/toxins8040093</pub-id><pub-id pub-id-type="pmid">27023608</pub-id>
</element-citation></ref><ref id="B54-vetsci-11-00605"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siigur</surname><given-names>E.</given-names></name>
<name><surname>Aasp&#x000f5;llu</surname><given-names>A.</given-names></name>
<name><surname>Siigur</surname><given-names>J.</given-names></name>
</person-group><article-title>Sequence Diversity of Vipera Lebetina Snake Venom Gland Serine Proteinase Homologs--Result of Alternative-Splicing or Genome Alteration</article-title><source>Gene</source><year>2001</year><volume>263</volume><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(00)00571-0</pub-id><pub-id pub-id-type="pmid">11223258</pub-id>
</element-citation></ref><ref id="B55-vetsci-11-00605"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
<name><surname>Marcinkiewicz</surname><given-names>C.</given-names></name>
<name><surname>Sanz</surname><given-names>L.</given-names></name>
</person-group><article-title>Snake Venomics of Bitis Gabonica Gabonica. Protein Family Composition, Subunit Organization of Venom Toxins, and Characterization of Dimeric Disintegrins Bitisgabonin-1 and Bitisgabonin-2</article-title><source>J. Proteome Res.</source><year>2007</year><volume>6</volume><fpage>326</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1021/pr060494k</pub-id><pub-id pub-id-type="pmid">17203976</pub-id>
</element-citation></ref><ref id="B56-vetsci-11-00605"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogawa</surname><given-names>T.</given-names></name>
<name><surname>Chijiwa</surname><given-names>T.</given-names></name>
<name><surname>Oda-Ueda</surname><given-names>N.</given-names></name>
<name><surname>Ohno</surname><given-names>M.</given-names></name>
</person-group><article-title>Molecular Diversity and Accelerated Evolution of C-Type Lectin-like Proteins from Snake Venom</article-title><source>Toxicon Off. J. Int. Soc. Toxinol.</source><year>2005</year><volume>45</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2004.07.028</pub-id></element-citation></ref><ref id="B57-vetsci-11-00605"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van den Berg</surname><given-names>L.M.</given-names></name>
<name><surname>Gringhuis</surname><given-names>S.I.</given-names></name>
<name><surname>Geijtenbeek</surname><given-names>T.B.H.</given-names></name>
</person-group><article-title>An Evolutionary Perspective on C-Type Lectins in Infection and Immunity</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2012</year><volume>1253</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2011.06392.x</pub-id><pub-id pub-id-type="pmid">22288724</pub-id>
</element-citation></ref><ref id="B58-vetsci-11-00605"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
<name><surname>Marcinkiewicz</surname><given-names>C.</given-names></name>
<name><surname>Monle&#x000f3;n</surname><given-names>D.</given-names></name>
<name><surname>Esteve</surname><given-names>V.</given-names></name>
<name><surname>Celda</surname><given-names>B.</given-names></name>
<name><surname>Ju&#x000e1;rez</surname><given-names>P.</given-names></name>
<name><surname>Sanz</surname><given-names>L.</given-names></name>
</person-group><article-title>Snake Venom Disintegrins: Evolution of Structure and Function</article-title><source>Toxicon Off. J. Int. Soc. Toxinol.</source><year>2005</year><volume>45</volume><fpage>1063</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2005.02.024</pub-id></element-citation></ref><ref id="B59-vetsci-11-00605"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
</person-group><article-title>The Continuing Saga of Snake Venom Disintegrins</article-title><source>Toxicon Off. J. Int. Soc. Toxinol.</source><year>2013</year><volume>62</volume><fpage>40</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2012.09.005</pub-id></element-citation></ref><ref id="B60-vetsci-11-00605"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Milovanovic</surname><given-names>V.</given-names></name>
<name><surname>Minic</surname><given-names>R.</given-names></name>
<name><surname>Vakic</surname><given-names>J.</given-names></name>
<name><surname>Ivanovic</surname><given-names>S.</given-names></name>
<name><surname>Cupic</surname><given-names>V.</given-names></name>
<name><surname>Borozan</surname><given-names>S.</given-names></name>
<name><surname>Nesic</surname><given-names>A.</given-names></name>
<name><surname>Zivkovic</surname><given-names>I.</given-names></name>
</person-group><article-title>MTT Based L-Aminoacid Oxidase Activity Test for Determination of Antivenom Potency against Vipera Ammodytes Envenomation</article-title><source>Toxicon Off. J. Int. Soc. Toxinol.</source><year>2021</year><volume>192</volume><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2021.01.012</pub-id></element-citation></ref><ref id="B61-vetsci-11-00605"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
</person-group><article-title>Phospholipases A2: Unveiling the Secrets of a Functionally Versatile Group of Snake Venom Toxins</article-title><source>Toxicon Off. J. Int. Soc. Toxinol.</source><year>2013</year><volume>62</volume><fpage>27</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2012.09.006</pub-id><pub-id pub-id-type="pmid">23025922</pub-id>
</element-citation></ref><ref id="B62-vetsci-11-00605"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osipov</surname><given-names>A.</given-names></name>
<name><surname>Utkin</surname><given-names>Y.</given-names></name>
</person-group><article-title>Effects of Snake Venom Polypeptides on Central Nervous System</article-title><source>Cent. Nerv. Syst. Agents Med. Chem.</source><year>2012</year><volume>12</volume><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.2174/187152412803760618</pub-id><pub-id pub-id-type="pmid">23270323</pub-id>
</element-citation></ref><ref id="B63-vetsci-11-00605"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>AlShammari</surname><given-names>A.K.</given-names></name>
<name><surname>Abd El-Aziz</surname><given-names>T.M.</given-names></name>
<name><surname>Al-Sabi</surname><given-names>A.</given-names></name>
</person-group><article-title>Snake Venom: A Promising Source of Neurotoxins Targeting Voltage-Gated Potassium Channels</article-title><source>Toxins</source><year>2023</year><volume>16</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.3390/toxins16010012</pub-id><pub-id pub-id-type="pmid">38251229</pub-id>
</element-citation></ref><ref id="B64-vetsci-11-00605"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Logonder</surname><given-names>U.</given-names></name>
<name><surname>Krizaj</surname><given-names>I.</given-names></name>
<name><surname>Rowan</surname><given-names>E.G.</given-names></name>
<name><surname>Harris</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Neurotoxicity of Ammodytoxin a in the Envenoming Bites of Vipera Ammodytes Ammodytes</article-title><source>J. Neuropathol. Exp. Neurol.</source><year>2008</year><volume>67</volume><fpage>1011</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e318188c2d7</pub-id><pub-id pub-id-type="pmid">18800006</pub-id>
</element-citation></ref><ref id="B65-vetsci-11-00605"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Z.</given-names></name>
<name><surname>Yu</surname><given-names>B.</given-names></name>
</person-group><article-title>Role of Presynaptic Acetylcholine Autoreceptors at Motor Nerve Endings on Tetanic and Train-of-Four Fade Seen during a Nondepolarizing Neuromuscular Block</article-title><source>Anesthesiology</source><year>2007</year><volume>106</volume><fpage>1243</fpage><pub-id pub-id-type="doi">10.1097/01.anes.0000265457.47797.4c</pub-id><pub-id pub-id-type="pmid">17525604</pub-id>
</element-citation></ref><ref id="B66-vetsci-11-00605"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jonsson</surname><given-names>M.</given-names></name>
<name><surname>Eriksson</surname><given-names>L.I.</given-names></name>
</person-group><article-title>Role of Presynaptic Acetylcholine Autoreceptors at Motor Nerve Endings on Tetanic and Train-of-Four Fade Seen during a Nondepolarizing Neuromuscular Block</article-title><source>Anesthesiology</source><year>2007</year><volume>106</volume><fpage>1243</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1097/01.anes.0000265462.01331.91</pub-id><pub-id pub-id-type="pmid">17525604</pub-id>
</element-citation></ref><ref id="B67-vetsci-11-00605"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alves-do-Prado</surname><given-names>W.</given-names></name>
<name><surname>Corrado</surname><given-names>A.P.</given-names></name>
<name><surname>Prado</surname><given-names>W.A.</given-names></name>
</person-group><article-title>Reversal by Atropine of Tetanic Fade Induced in Cats by Antinicotinic and Anticholinesterase Agents</article-title><source>Anesth. Analg.</source><year>1987</year><volume>66</volume><fpage>492</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1213/00000539-198706000-00002</pub-id><pub-id pub-id-type="pmid">2883915</pub-id>
</element-citation></ref><ref id="B68-vetsci-11-00605"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faria</surname><given-names>M.</given-names></name>
<name><surname>Oliveira</surname><given-names>L.</given-names></name>
<name><surname>Tim&#x000f3;teo</surname><given-names>M.A.</given-names></name>
<name><surname>Lobo</surname><given-names>M.G.</given-names></name>
<name><surname>Correia-De-S&#x000e1;</surname><given-names>P.</given-names></name>
</person-group><article-title>Blockade of Neuronal Facilitatory Nicotinic Receptors Containing Alpha 3 Beta 2 Subunits Contribute to Tetanic Fade in the Rat Isolated Diaphragm</article-title><source>Synapse</source><year>2003</year><volume>49</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1002/syn.10211</pub-id><pub-id pub-id-type="pmid">12740863</pub-id>
</element-citation></ref><ref id="B69-vetsci-11-00605"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frobert</surname><given-names>Y.</given-names></name>
<name><surname>Cr&#x000e9;minon</surname><given-names>C.</given-names></name>
<name><surname>Cousin</surname><given-names>X.</given-names></name>
<name><surname>R&#x000e9;my</surname><given-names>M.H.</given-names></name>
<name><surname>Chatel</surname><given-names>J.M.</given-names></name>
<name><surname>Bon</surname><given-names>S.</given-names></name>
<name><surname>Bon</surname><given-names>C.</given-names></name>
<name><surname>Grassi</surname><given-names>J.</given-names></name>
</person-group><article-title>Acetylcholinesterases from Elapidae Snake Venoms: Biochemical, Immunological and Enzymatic Characterization</article-title><source>Biochim. Biophys. Acta</source><year>1997</year><volume>1339</volume><fpage>253</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/S0167-4838(97)00009-5</pub-id><pub-id pub-id-type="pmid">9187246</pub-id>
</element-citation></ref><ref id="B70-vetsci-11-00605"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benziane</surname><given-names>B.</given-names></name>
<name><surname>Bj&#x000f6;rnholm</surname><given-names>M.</given-names></name>
<name><surname>Pirkmajer</surname><given-names>S.</given-names></name>
<name><surname>Austin</surname><given-names>R.L.</given-names></name>
<name><surname>Kotova</surname><given-names>O.</given-names></name>
<name><surname>Viollet</surname><given-names>B.</given-names></name>
<name><surname>Zierath</surname><given-names>J.R.</given-names></name>
<name><surname>Chibalin</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Activation of AMP-Activated Protein Kinase Stimulates Na+,K+-ATPase Activity in Skeletal Muscle Cells</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>23451</fpage><lpage>23463</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.331926</pub-id><pub-id pub-id-type="pmid">22610379</pub-id>
</element-citation></ref><ref id="B71-vetsci-11-00605"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rolfe</surname><given-names>D.F.</given-names></name>
<name><surname>Brown</surname><given-names>G.C.</given-names></name>
</person-group><article-title>Cellular Energy Utilization and Molecular Origin of Standard Metabolic Rate in Mammals</article-title><source>Physiol. Rev.</source><year>1997</year><volume>77</volume><fpage>731</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1152/physrev.1997.77.3.731</pub-id><pub-id pub-id-type="pmid">9234964</pub-id>
</element-citation></ref><ref id="B72-vetsci-11-00605"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ereci&#x00144;ska</surname><given-names>M.</given-names></name>
<name><surname>Silver</surname><given-names>I.A.</given-names></name>
</person-group><article-title>ATP and Brain Function</article-title><source>J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.</source><year>1989</year><volume>9</volume><fpage>2</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.1989.2</pub-id><pub-id pub-id-type="pmid">2642915</pub-id>
</element-citation></ref><ref id="B73-vetsci-11-00605"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clausen</surname><given-names>T.</given-names></name>
<name><surname>Van Hardeveld</surname><given-names>C.</given-names></name>
<name><surname>Everts</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Significance of Cation Transport in Control of Energy Metabolism and Thermogenesis</article-title><source>Physiol. Rev.</source><year>1991</year><volume>71</volume><fpage>733</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1152/physrev.1991.71.3.733</pub-id><pub-id pub-id-type="pmid">2057526</pub-id>
</element-citation></ref><ref id="B74-vetsci-11-00605"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ivanu&#x00161;ec</surname><given-names>A.</given-names></name>
<name><surname>&#x00160;ribar</surname><given-names>J.</given-names></name>
<name><surname>Verani&#x0010d;</surname><given-names>P.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
</person-group><article-title>The Phospholipase Activity of Ammodytoxin, a Prototype Snake Venom &#x003b2;-Neurotoxin, Is Not Obligatory for Cell Internalisation and Translocation to Mitochondria</article-title><source>Toxins</source><year>2022</year><volume>14</volume><elocation-id>375</elocation-id><pub-id pub-id-type="doi">10.3390/toxins14060375</pub-id><pub-id pub-id-type="pmid">35737036</pub-id>
</element-citation></ref><ref id="B75-vetsci-11-00605"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Logonder</surname><given-names>U.</given-names></name>
<name><surname>Jenko-Praznikar</surname><given-names>Z.</given-names></name>
<name><surname>Scott-Davey</surname><given-names>T.</given-names></name>
<name><surname>Pungercar</surname><given-names>J.</given-names></name>
<name><surname>Krizaj</surname><given-names>I.</given-names></name>
<name><surname>Harris</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Ultrastructural Evidence for the Uptake of a Neurotoxic Snake Venom Phospholipase A2 into Mammalian Motor Nerve Terminals</article-title><source>Exp. Neurol.</source><year>2009</year><volume>219</volume><fpage>591</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2009.07.017</pub-id><pub-id pub-id-type="pmid">19631643</pub-id>
</element-citation></ref><ref id="B76-vetsci-11-00605"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheng</surname><given-names>Z.-H.</given-names></name>
<name><surname>Cai</surname><given-names>Q.</given-names></name>
</person-group><article-title>Mitochondrial Transport in Neurons: Impact on Synaptic Homeostasis and Neurodegeneration</article-title><source>Nat. Rev. Neurosci.</source><year>2012</year><volume>13</volume><fpage>77</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nrn3156</pub-id><pub-id pub-id-type="pmid">22218207</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-11-00605-f001"><label>Figure 1</label><caption><p><italic toggle="yes">Vipera ammodytes ammodytes</italic>. Original photo: Institute of Virology, Vaccines and Sera &#x0201c;Torlak&#x0201d;, Belgrade, Serbia.</p></caption><graphic xlink:href="vetsci-11-00605-g001" position="float"/></fig><fig position="float" id="vetsci-11-00605-f002"><label>Figure 2</label><caption><p>(<bold>A</bold>) Distribution of identified proteins for fraction 0 when different protein FASTA databases were used in the analysis; (<bold>B</bold>) Distribution of identified proteins for all fractions (0, 3A, 5A, 8A, 9A and 10A) when <italic toggle="yes">Serpentes</italic> protein FASTA databases (DB) were used in the analysis; (<bold>C</bold>) Distribution of identified proteins for all fractions (0, 3A, 5A, 8A, 9A and 10A) when <italic toggle="yes">Vipera</italic> protein FASTA databases (DB) were used in the analysis; (<bold>D</bold>) Distribution of identified proteins for all fractions (0, 3A, 5A, 8A, 9A and 10A) when <italic toggle="yes">V. ammodytes</italic> protein FASTA databases (DB) were used in the analysis; (<bold>E</bold>) Distribution of identified proteins for all fractions (0, 3A, 5A, 8A, 9A and 10A) when different protein FASTA databases were used in the analysis. Next to each fraction, the number of proteins identified in this fraction for all three databases used is given in brackets.</p></caption><graphic xlink:href="vetsci-11-00605-g002" position="float"/></fig><fig position="float" id="vetsci-11-00605-f003"><label>Figure 3</label><caption><p>Relative distribution of protein groups (%) in the <italic toggle="yes">Vaa</italic> venom determined by nano-liquid chromatography&#x02013;tandem mass spectrometry-based proteomics: (<bold>A</bold>) DB <italic toggle="yes">V. ammodytes</italic>; (<bold>B</bold>) DB <italic toggle="yes">Vipera</italic>.</p></caption><graphic xlink:href="vetsci-11-00605-g003" position="float"/></fig><fig position="float" id="vetsci-11-00605-f004"><label>Figure 4</label><caption><p>Representative recording of contractions of a neuromuscular preparation of the diaphragm (NPD) induced by indirect EFS (&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;) in the absence of venom. C<sub>1</sub> and C<sub>2</sub>&#x02014;control contractions; panc 1 &#x003bc;M&#x02014;contractions under the influence of 1 &#x003bc;M pancuronium; W<sub>1</sub> and W<sub>2</sub>&#x02014;contractions after the washout of pancuronium; 10 &#x0201c;packages&#x0201d; of contractions in the function of time.</p></caption><graphic xlink:href="vetsci-11-00605-g004" position="float"/></fig><fig position="float" id="vetsci-11-00605-f005"><label>Figure 5</label><caption><p>Representative recording of contractions of a neuromuscular preparation of the diaphragm (NPD) induced by indirect EFS (<bold>&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;</bold>) and direct EFS (<bold>-----</bold>) under the influence of venom. C<sub>1</sub> and C<sub>2</sub>&#x02014;control contractions; panc 3 &#x003bc;M&#x02014;contractions under the influence of 3 &#x003bc;M pancuronium; W<sub>1</sub> and W<sub>2</sub>&#x02014;contractions after the washout of pancuronium; 12 &#x0201c;packages&#x0201d; of contractions induced by indirect EFS; 2 &#x0201c;packages&#x0201d; of contractions induced by direct EFS.</p></caption><graphic xlink:href="vetsci-11-00605-g005" position="float"/></fig><fig position="float" id="vetsci-11-00605-f006"><label>Figure 6</label><caption><p>Sigmoidal curves of the reduction in contractions of the neuromuscular preparation of the diaphragm (NPD) in a logarithmic function of time under the influence of venom and venom/antivenom mixtures at ratios of 1:2; 1:10 and 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>).</p></caption><graphic xlink:href="vetsci-11-00605-g006" position="float"/></fig><fig position="float" id="vetsci-11-00605-f007"><label>Figure 7</label><caption><p>Comparison of ET<sub>50</sub> (minutes) after the administration of venom and a venom/antivenom mixture at the ratios of 1:2; 1:10 and 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) (mean &#x000b1; SD, <sup>#</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.05, <sup>###</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.001 vs. venom; <sup>+++</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.001 between different mass ratios of venom/antivenom).</p></caption><graphic xlink:href="vetsci-11-00605-g007" position="float"/></fig><fig position="float" id="vetsci-11-00605-f008"><label>Figure 8</label><caption><p>Representative recording of contraction peaks of the neuromuscular preparations of the diaphragm (NPD) induced by indirect EFS: (<bold>A</bold>) Control contractions; (<bold>B</bold>) Contractions under the influence of pancuronium <italic toggle="yes">(tetanic fade)</italic>; (<bold>C</bold>) Contractions under the influence of venom; (<bold>D</bold>) Contractions under the influence of a mixture of venom/antivenom at a ratio of 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) (white arrows show a facilitated release of neurotransmitters; black arrows show a reduced release of neurotransmitters&#x02014;<italic toggle="yes">tetanic fade</italic>).</p></caption><graphic xlink:href="vetsci-11-00605-g008" position="float"/></fig><fig position="float" id="vetsci-11-00605-f009"><label>Figure 9</label><caption><p>AChE activity (U/mg P) in the neuromuscular preparations of the diaphragm (NPD) without the presence of venom (control), under the influence of venom and for the mixture of venom/antivenom at a ratio of 1:2, 1:10 and 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) (mean &#x000b1; SD, <italic toggle="yes">p</italic> &#x0003e; 0.05).</p></caption><graphic xlink:href="vetsci-11-00605-g009" position="float"/></fig><fig position="float" id="vetsci-11-00605-f010"><label>Figure 10</label><caption><p>Na<sup>+</sup>/K<sup>+</sup>-ATPase activity (U/mg P) in the neuromuscular preparations of the diaphragm (NPD) without the presence of venom (control), under the influence of venom and under the influence of a mixture of venom and antivenom at the ratios of 1:2; 1:10 and 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) (mean &#x000b1; SD, *** <italic toggle="yes">p</italic> &#x0003c; 0.001 vs. control; <sup>##</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.01, <sup>###</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.001 vs. venom; <sup>++</sup>
<italic toggle="yes">p</italic>&#x0003c;0.01 between different mass ratios of venom/antivenom).</p></caption><graphic xlink:href="vetsci-11-00605-g010" position="float"/></fig><fig position="float" id="vetsci-11-00605-f011"><label>Figure 11</label><caption><p>(<bold>A</bold>) Activity of the PLA2 in increasing concentrations of the <italic toggle="yes">Vaa</italic> venom (mg/mL); (<bold>B</bold>) Inhibition of the PLA2 activity in 1 mg/mL of the <italic toggle="yes">Vaa</italic> venom by increasing concentrations of the antivenom (mg/mL).</p></caption><graphic xlink:href="vetsci-11-00605-g011" position="float"/></fig><table-wrap position="float" id="vetsci-11-00605-t001"><object-id pub-id-type="pii">vetsci-11-00605-t001_Table 1</object-id><label>Table 1</label><caption><p>Phospholipases (PLA2) of the venom of <italic toggle="yes">V. ammodytes</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mw (kDa)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">pI</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relative Abundance<break/>of Protein Groups (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Enzyme Activity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Enzyme Action</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ammodytoxins&#x02014;Atxs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Presynaptic neurotoxins</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ammodytoxin A <break/>(AtxA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">active</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Most toxic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ammodytoxin B<break/>(AtxB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">active</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">* 28 times less toxic than AtxA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ammodytoxin C<break/>(AtxC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">active</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">* 17 times less toxic than AtxA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ammodytins&#x02014;Atns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ammodytin L<break/>(AtnL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">inactive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myotoxic, cardiotoxic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ammodytin I1<break/>(AtnI1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">active</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-toxic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ammodytin I2<break/>(AtnI2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.3<break/>15.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.47<break/>5.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.45<break/>1.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">active</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-toxic</td></tr></tbody></table><table-wrap-foot><fn><p>* [<xref rid="B42-vetsci-11-00605" ref-type="bibr">42</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vetsci-11-00605-t002"><object-id pub-id-type="pii">vetsci-11-00605-t002_Table 2</object-id><label>Table 2</label><caption><p>Decrease in diaphragmatic contractility as a function of time under the influence of venom and venom/antivenom mixtures in different mass ratios (1:2; 1:10; 1:20).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Time<break/>(min)</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">The Mean Values of the NPD Contractions (%) Compared to the Control Contractions</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venom</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venom/Antivenom<break/>1:2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venom/Antivenom<break/>1:10</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venom/Antivenom<break/>1:20</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">90.95</td><td align="center" valign="middle" rowspan="1" colspan="1">96.55</td><td align="center" valign="middle" rowspan="1" colspan="1">97.78</td><td align="center" valign="middle" rowspan="1" colspan="1">93.60</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">79.13</td><td align="center" valign="middle" rowspan="1" colspan="1">84.61</td><td align="center" valign="middle" rowspan="1" colspan="1">89.51</td><td align="center" valign="middle" rowspan="1" colspan="1">89.92</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">45</td><td align="center" valign="middle" rowspan="1" colspan="1">64.15</td><td align="center" valign="middle" rowspan="1" colspan="1">72.20</td><td align="center" valign="middle" rowspan="1" colspan="1">76.26</td><td align="center" valign="middle" rowspan="1" colspan="1">86.08</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="center" valign="middle" rowspan="1" colspan="1">52.68</td><td align="center" valign="middle" rowspan="1" colspan="1">61.47</td><td align="center" valign="middle" rowspan="1" colspan="1">71.13</td><td align="center" valign="middle" rowspan="1" colspan="1">88.27</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">40.74</td><td align="center" valign="middle" rowspan="1" colspan="1">46.64</td><td align="center" valign="middle" rowspan="1" colspan="1">66.01</td><td align="center" valign="middle" rowspan="1" colspan="1">81.50</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">90</td><td align="center" valign="middle" rowspan="1" colspan="1">31.49</td><td align="center" valign="middle" rowspan="1" colspan="1">40.67</td><td align="center" valign="middle" rowspan="1" colspan="1">63.21</td><td align="center" valign="middle" rowspan="1" colspan="1">80.76</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">105</td><td align="center" valign="middle" rowspan="1" colspan="1">24.35</td><td align="center" valign="middle" rowspan="1" colspan="1">34.79</td><td align="center" valign="middle" rowspan="1" colspan="1">60.30</td><td align="center" valign="middle" rowspan="1" colspan="1">74.09</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">120</td><td align="center" valign="middle" rowspan="1" colspan="1">16.56</td><td align="center" valign="middle" rowspan="1" colspan="1">30.50</td><td align="center" valign="middle" rowspan="1" colspan="1">54.86</td><td align="center" valign="middle" rowspan="1" colspan="1">72.49</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">135</td><td align="center" valign="middle" rowspan="1" colspan="1">14.93</td><td align="center" valign="middle" rowspan="1" colspan="1">21.64</td><td align="center" valign="middle" rowspan="1" colspan="1">48.91</td><td align="center" valign="middle" rowspan="1" colspan="1">68.71</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">150</td><td align="center" valign="middle" rowspan="1" colspan="1">12.30</td><td align="center" valign="middle" rowspan="1" colspan="1">18.00</td><td align="center" valign="middle" rowspan="1" colspan="1">36.56</td><td align="center" valign="middle" rowspan="1" colspan="1">67.11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">165</td><td align="center" valign="middle" rowspan="1" colspan="1">10.36</td><td align="center" valign="middle" rowspan="1" colspan="1">13.15</td><td align="center" valign="middle" rowspan="1" colspan="1">29.45</td><td align="center" valign="middle" rowspan="1" colspan="1">67.06</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">180</td><td align="center" valign="middle" rowspan="1" colspan="1">8.78</td><td align="center" valign="middle" rowspan="1" colspan="1">10.54</td><td align="center" valign="middle" rowspan="1" colspan="1">22.61</td><td align="center" valign="middle" rowspan="1" colspan="1">67.26</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">195</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">61.65</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">210</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">58.79</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">225</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.90</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-11-00605-t003"><object-id pub-id-type="pii">vetsci-11-00605-t003_Table 3</object-id><label>Table 3</label><caption><p>Calculated ET<sub>50</sub> (minutes) after the administration of venom and venom/antivenom mixture at the ratios 1:2; 1:10 and 1:20 (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) (mean &#x000b1; SD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Venom and Venom/Antivenom Mixtures <break/>at Different Mass Ratios</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Venom</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Venom/Antivenom<break/> 1:2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Venom/Antivenom<break/>1:10</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Venom/Antivenom <break/>1:20</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ET<sub>50</sub> (minutes)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.17 &#x000b1; 2.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73.29 &#x000b1; 3.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114.80 &#x000b1; 12.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">317.80 &#x000b1; 40.46</td></tr></tbody></table></table-wrap></floats-group></article>